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Adaptive immunity is the foundation of recognition and protection against a 
diverse array of pathogens. The humoral arm of adaptive immunity whose most 
significant effector mechanism relies on antibodies is critical for protection against many 
viral and bacterial pathogens.  Additionally, antibodies are extremely important for 
clinical medicine either as therapeutics or for detection purposes. As a result, there is 
great interest in the development of technologies for isolating therapeutically or 
diagnostically useful antibodies from immunized animals or from patients. 
In this work I describe several high throughput approaches for the “mining” of the 
mammalian adaptive antibody response for the purpose of isolating antibodies with high 
affinity and selectivity towards desired antigens. The first technology capitalizes on the 
fact that the antibody repertoire encoded by B cells in the draining lymph node from the 
immunization site is highly enriched for antibodies specific to the immunogen. The 
second technology takes advantage of repertoire analysis by next-generation sequencing 
and yeast display for antibody discovery. The third technology integrates high-throughput 
VH:VL pairing with yeast surface display to enable rapid, high-throughput screening of all 
native antibodies in the repertoire. These three technologies have been used to identify a 
 viii 
large panel of antibodies against several different pathogens, including Ebola virus, ricin, 
influenza virus, and HIV-1 virus.  
These technologies will continue to play a critical role in adaptive immunity 
exploration for new therapeutics discovery, and in characterization of immune responses 
elicited by vaccination or natural infection to guide design of more effective vaccines. 
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Chapter 1: Introduction 
The immune system is specialized to recognize and fight against various arrays of 
exogenous and self pathogens (in autoimmunity). As the first defense, innate immunity, 
including complement pathways, phagocytosis by neutrophils, macrophages, and 
dendritic cells, and cytotoxicity by natural killer cells (NK) and eosinophils, helps to 
clear most common pathogens directly. However, when innate immunity fails (Kumar et 
al., 2011), adaptive immune responses that are tailored to recognize molecular features of 
the pathogen that is posing a challenge to the organism takes over. Adaptive immunity 
provides the basis for recognition of, and protection from, numerous pathogenic cells and 
viruses. There are two branches of adaptive immunity: B cell based humoral immunity 
and T cell based cellular immunity (Boehm, 2011).  The effector arm of B cell immunity 
is mediated by the production of antibodies, while T cells destroy cells with intracellular 
pathogens and help with B cell activation. 
ANTIBODY STRUCTURES 
Antibodies are a class of protein molecules secreted by B cells. They can not only 
recognize pathogens, but also opsonize them to initiate pathogen clearance by other 
effector cells. Hence, antibodies are very important effector molecules that protect host 
organisms from pathogenesis, and they connect adaptive immunity with innate immunity. 
The modular structures of antibodies are indispensable for their functions, which also 
make them convenient to manipulate. This modularity also forms part of the foundation 
of antibody discovery and engineering. 
Antibodies are ‘Y’ shaped symmetric homodimers of heterodimers, and each 
heterodimer is made of 1 heavy chain and 1 light chain. In humans, there are 5 different 
kinds of heavy chains (isotypes), IgG, IgA, IgE, IgM, and IgD, , which are encoded by 
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constant γ (including 4 subtypes, γ1, γ2, γ3, and γ4, with γ1 being the most abundant), α 
(including 2 subtypes, α1 and α2), ε, μ, and δ regions, respectively (Fig. 1-1). There are 
also 2 different kinds of light chains, kappa (κ) and lambda (λ), which can both pair with 
heavy chains. The heavy chain has 4 immunoglobulin superfamily (IgSF) domains (5 for 
IgM and IgE), namely VH (variable heavy), CH1 (constant heavy), CH2, and CH3 (CH4 for 
IgM and IgE), while the light chain has 2 IgSF domains, VL (variable light) and CL 
(constant light). Each IgSF domain is a 70-110 amino acid (aa) long, sandwich-like 
structure formed by antiparallel β-sheets that have a hydrophobic inner core and 
conserved cysteines that form disulfide bonds. Each heterodimer of 1 heavy chain and 1 
light chain is also connected by 1 conserved disulfide bond between the CH1 and CL 
domains, The two heterodimers are also connected by conserved disulfide bonds in the 
hinge region. IgG, IgD, and IgE antibodies are monomeric, while IgM are pentameric, 
and IgA are dimeric or monomeric. The multimerization of IgM and IgA is mediated by a 
small polypeptide called the J chain. Multimerization can significantly enhance the 
apparent affinity of IgM or IgA and also facilitates transport, especially of IgA across 
epithelial cells for secretion to mucosal surfaces. 
The entire antibody molecule can be separated into 3 parts: 2 antigen binding 
fragments (Fab) and 1 crystallizable fragment (Fc). The Fab fragment binds antigen with 
contributions from both the VH and VL, while the Fc fragment binds to Fc receptors 
expressed on different cells. This interaction is very important for antibody effector 
functions, extending the antibody half-life, and linking innate immunity to adaptive 
immunity. Different antibody isotypes have diverse effector functions. IgG antibodies 
usually elicit cytotoxicity and phagocytosis by binding to different Fcγ receptors 
expressed on various innate immune cells (including natural killer cells (NK), 
neutrophils, macrophages, and dendritic cells), IgE antibodies induce inflammation by 
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binding to Fcε receptors expressed on mast cells, while IgA antibodies elicit phagocytosis 
by binding to Fcα receptors expressed on certain cellular subsets (including neutrophils, 
macrophages, and Kuppfer cells). Another important Fc receptor is the neonatal Fc 
receptor (FcRn), which only IgG can bind to. The binding of IgG to FcRn provides the 
molecular basis for the long half-life of IgG in the serum, which explains why most 
therapeutic antibodies are of IgG isotype. Different FcRs have cytoplasmic domains that 
contain different signaling motifs, either activating immunoreceptor tyrosine-based 
activation motifs (ITAMs) or inhibiting immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs), which determine downstream signaling pathways after antibody binding to the 
FcR.  Notably, the Asn-Ser-Thr motif in the CH2 domain where Asn is glycosylated is 
indispensable for FcR binding, and the glycan composition has large effects on FcR 
specificity and affinity. 
Previous research has shown that there are 3 regions within the VH and VL 
domains that show very high variability, namely heavy chain complementary determining 
regions (CDRH) 1, 2, 3, and light chain CDRL 1, 2, 3 (Johnson and Wu, 2004) (Fig. 1-2). 
These 6 CDRs are supported by 4 framework regions (FR) on each chain, and they 
determine much of the specificity and affinity of the antibody to the antigen by forming 
the main contact interface between the two. This provides the structural basis of antibody 
recognition of diverse antigens. Within these 6 CDRs, CDRH3 is the most variable and is 
typically thought to contribute the most to antigen binding. It is noteworthy to mention 
that these 6 CDRs, especially CDRH3, are not only variable in the amino acid 
compositions, but also in their lengths. The discovery of HIV-1 broadly neutralizing 
antibodies (bnAbs) that have longer than 30 aa CDRH3s shows the effectiveness of long 
CDRs to penetrate viral glycan shields to target conserved epitopes (Doria-Rose et al., 
2014). 
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On the other hand, whether such a diverse amino acid composition in CDRs is 
essential for binding is under investigation, as previous research has shown that high-
affinity binding to some antigens can still be achieved with just Tyr and Ser in CDRs 
(Fellouse et al., 2004; Persson et al., 2013). However, a more diverse aa composition 
provides a larger sequence space for the immune system to search through, which ensures 
a higher success rate to identify antibodies specific for an antigen. 
As a result of the large size of full-length antibodies, several different formats of 
small antibody fragments have been engineered. The most common format is that of the 
single chain fragment variable (scFv), which is a VH linked to a VL with a flexible linker, 
usually (Gly4Ser)3, and the other common format is that of the Fab (Fig. 1-3). These 
fragments can be easily functionally expressed in E. coli and yeast with high yields. 
However, the reconstitution of a scFv as an IgG antibody after the identification of 
antigen-specific clones is usually necessary, and sometimes this may result in a loss of 
binding. It is noteworthy to mention that some species, including lamas, produce 
antibodies that only have heavy chains, from which nanobodies (VH) have been designed 
(Muyldermans, 2013). Nanobodies are the smallest antigen binding fragment. 
Since the Fc fragment is not involved in antigen binding, only Fab fragments need 
to be engineered to select for antibodies that bind different antigens. Furthermore, as 
CDRs contribute the most to antigen binding, the antibody selection procedure can be 
focused more specifically on CDR engineering. 
Finally, the modular structure of antibodies also inspired the design and 
engineering of novel antibody formats, with the most well-known one being that of a 
bispecific antibody, which has two different Fab fragments in one single antibody 
molecule (Chan and Carter, 2010). Several different techniques have been developed for 
bispecific antibody production, including Fab arm exchange (Labrijn et al., 2013), and 
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the introduction of mutations to favor heterodimer formation and prevent homodimer 
formation (Lewis et al., 2014). Spiess et al. recently demonstrated co-culture of E. coli 
strains that express two half-antibodies (1 heavy chain and 1 light chain), and purification 
and combination of the half-antibodies to make the entire bispecific antibodies (Spiess et 
al., 2013). The US Food and Drug Administration (FDA) approval of the bispecific 
Blinatumomab (CD19 and CD3 targeting) demonstrated the therapeutic potential of 
bispecific antibodies and encouraged more effort towards their development (Goebeler et 
al., 2016). 
Other formats of antibodies include the minibody, diabody, tetrabody, and the 
IgG-scFv (Chan and Carter, 2010). However, the therapeutic potential of these antibody 
formats are yet to be tested, and a large potential problem for in vivo use of these 
antibody formats is their immunogenicity, which is a result of their ‘irregular’ structures 
compared to that of normal antibodies. 
IMMUNOGLOBULIN LOCI AND B CELL DEVELOPMENT 
Based on the well-known International Immunogenetics Information System 
(IMGT) database (Giudicelli and Lefranc, 1999; Giudicelli et al., 2006; Lefranc et al., 
2009), there are 56 V (variable), 23 D (diversity), and 6 J (junction) segments for the VH 
domain, 38 V and 5 J for Vκ domain, and 35 V and 7 J for Vλ domain in the human 
genome. These genes are located on chromosomes 14 (14q32.33), 2 (2p11.2), and 22 
(22q11.2), respectively. During the development of B cells, these genes need to be joined 
together to form productive VH and VL domains. 
The unique developmental process of B cells provides the foundation for the 
generation of a diverse repertoire of antibodies (Dudley et al., 2005; Li et al., 2004; Nadel 
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and Feeney, 1997; Tonegawa, 1983). There are two different sequence diversification 
mechanisms, somatic recombination and somatic hypermutation. 
The first stage of B cell development occurs in the bone marrow and ends with 
the formation of IgM+ IgD+ naïve B cells. First, pro-B cells are derived from common 
lymphoid progenitors (CLP). During this process D and J genes are recombined first, 
followed by V genes recombining with DJ segments. After VDJ recombination, pre-B 
cell receptors (BCR) composed with rearranged productive heavy chain paired with a 
surrogate light chain consisting of VpreB and λ5 will be expressed on the surface of large 
pre-B cells. As a result of errors in gene rearrangement, cells with an unproductive pre-
BCR will become apoptotic and be eliminated. Hence, this serves as the first checkpoint 
for B cell development. 
After the large pre-B cell stage, V and J alleles for the light chain are recombined 
at the small pre-B cell stage. Productive VJ rearrangement results in the successful 
generation of a BCR , which replaces the pre-BCR on the surface. At this stage, only IgM 
is expressed on immature B cell surface. These IgM+ immature B cells are tested for auto-
reactivity, which serves as the second checkpoint for B cell development. Auto-reactive 
B cells can undergo either receptor editing (further gene rearrangement of light chain in a 
B cell that already has a productive light chain gene rearrangement) to have another 
chance to generate another BCR that is not auto-reactive, or become apoptotic and are 
eliminated. After this, the immature B cells start to express IgD on the surface and 
migrate to secondary lymphoid organs (lymph nodes, spleen). The IgM+IgD+ cells are 
now mature naïve B cells. 
Somatic recombination of V(D)J alleles is catalyzed by the recombination-
activating gene (RAG) complex composed of RAG-1 and RAG-2, the Ku70:80 complex, 
DNA-dependent protein kinase (DNA-PK), the Artemis complex, DNA ligase IV, and 
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terminal deoxynucleotidyl transferase (TdT). The RAG complex first recognizes the 
recombination signal sequences (RSS) that flank V(D)J alleles and brings them in 
proximity to excise parts of the chromosome. The to-be-joined segments with 
palindromic overhangs (P nucleotides) are then brought together, where TdT may then 
introduce non-templated nucleotides (N nucleotides). After that, the other complexes 
correct and complete the complementary strand, which leaves behind palindromic 
sequences. As a result of N/P nucleotide addition, the theoretical diversity of an antibody 
repertoire is estimated to be more than 1012. However, some studies using next-generation 
sequencing (NGS) showed that the actual diversity is only about 107 (Arnaout et al., 
2011; Boyd et al., 2009; Glanville et al., 2009). N/P nucleotides addition results in higher 
diversity in the CDRH3 and CDRL3 than that expected from V(D)J recombination only. 
Recent studies have shown that V(D)J recombination can also occur with other 
genes (Tan et al., 2016).  Tan et al. isolated broadly reactive malaria antibodies from two 
P. falciparum-negative donors, and found these antibodies have unusually long CDRH3s 
that are recombined not only from V(D)J alleles on chromosome 14, but also with 
LAIR1, an IgSF inhibitory receptor on chromosome 19 (Tan et al., 2016). The 
mechanism for this rare recombination event is still under investigation, but the genome 
instability of B cells after malaria infection may contribute to recombination of V(D)J 
and LAIR1 on different chromosomes (Robbiani et al., 2015). 
Before migration to secondary lymphoid organs, some mature naïve B cells 
develop into B-1 cells, which reside in pleural cavities and the peritoneum. B-1 cells 
produce natural antibodies, which usually do not undergo somatic hypermutation, and 
unlike B-2 cells that further develop in secondary lymphoid organs, they don’t need T 
cell help. Natural antibodies can usually only protect from pathogens with repeated 
molecular patterns (for example, phospholipids and carbohydrates). In contrast, B-2 cells 
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need T cell help for activation. In secondary lymphoid organs, these B cells reside in the 
follicles, and once activated through the binding to cognate antigens by their BCRs, they 
rapidly proliferate and differentiate into plasmablasts, and eventually short-lived plasma 
cells, both of which can secrete antibodies. A portion of activated B cells undergo 
germinal center reactions, during which they affinity mature their BCR for cognate 
antigens. In germinal centers, B cells travel back and forth between a light zone and dark 
zone. In the light zone, B cells with distinct BCRs that have different affinities to cognate 
antigens compete for the antigens, as well as for follicular dendritic cell and follicular T 
cell help. Those B cells with high affinities to antigens are then selected and stimulated. 
These stimulated B cells travel to dark zone and proliferate there. During proliferation, 
activation-induced cytidine deaminase introduces random mutations into the VH and VL 
domains. These B cells with mutated BCR sequences then travel back to the light zone, 
where a small portion of them that have beneficial affinity-improving mutations can get 
further help. Then they travel back again to dark zone to proliferate. The repeated cycling 
of B cells between the light zone and dark zone leads to BCR affinity maturation. 
Somatic hypermutation is not only the basis for the secondary diversification of antibody 
repertoires, but also controls antibody isotype switching (class-switch recombination). 
Perhaps the most significant example of somatic hypermutation is the 
identification of heavily mutated HIV-1 bnAbs (Corti and Lanzavecchia, 2013). The 
selection pressure that the constantly mutating HIV-1 virus exerts on the immune system, 
especially on B cells, forces them to constantly refine their BCR affinity and specificity. 
Different lineages of bnAbs that target different vulnerable sites on HIV-1 envelopes 
have been isolated after a long period of infection (usually several years) but not after a 
short time (Corti and Lanzavecchia, 2013; Doria-Rose et al., 2014; Liao et al., 2013). A 
large number of these HIV-1 bnAbs have more than 20% amino acid divergence from the 
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germline sequence. Specifically, the CD4 binding site targeting bnAb VRC01 has more 
than a 35% amino acid divergence (Wu et al., 2010). The long period of time required for 
bnAb generation and the high levels of somatic hypermutation indicate the importance of 
a high mutation load in the generation of bnAbs. 
Affinity-matured B cells can differentiate into either memory B cells, or 
plasmablasts. Memory B cells are usually long lived, and upon subsequent cognate 
antigen stimulation, they can either differentiate into plasmablasts and rapidly start 
antibody secretion, or undergo further affinity maturation in germinal centers. However, 
plasmablasts are short lived, but a fraction of them can home to specific niches in the 
bone marrow, where they become long-lived plasma cells, and can persist for up to 
several decades (Amanna et al., 2007; Höfer et al., 2006; Slifka et al., 1998). 
A detailed understanding of B cell development and adaptive immune responses 
constitutes the foundation of antibody repertoire characterization and antibody discovery. 
CHARACTERIZATION OF ANTIBODY REPERTOIRES 
As a result of somatic recombination and hypermutation, a diverse antibody 
repertoire is produced after antigenic challenge, thus making characterization of such a 
diverse repertoire a formidable task. Much effort has been made to advance techniques 
for antibody repertoire characterization, both at the cellular (antibody transcripts) level 
and at the serological (antibody proteins) level (Calis and Rosenberg, 2014; Corti et al., 
2011; Huang et al., 2012, 2014; Lavinder et al., 2014; Liao et al., 2013; Scheid et al., 
2009, 2011; Walker et al., 2009, 2011; Wine et al., 2013; Wrammert et al., 2008; Wu et 
al., 2010; Zhu et al., 2013a, 2013b). 
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Cellular antibody repertoire analysis 
Single-cell RT-PCR 
For the analysis of antibody transcripts, the single-cell reverse transcription 
polymerase chain reaction (RT-PCR) has been most widely used since its development 
(Wardemann et al., 2003). B cells from different sources (for example, from peripheral 
blood mononuclear cells (PBMCs) when analyzing human antibody repertoires, or from 
secondary lymphoid organs (lymph nodes and spleens) when analyzing mouse antibody 
repertoires) are first isolated using fluorescence activated cell sorting (FACS) and sorted 
into multi-well plates, with one cell in each well. Isolated single cells are lysed in situ, 
and RT-PCR is performed to amplify the VH and VL from single cells separately. The 
cognate VH:VL pairs from single B cells are sequenced, cloned, expressed and assayed. 
Wardemann et al. first used single-cell RT-PCR to investigate the origin of auto-
reactive B cells in human bone marrow and the mechanism for their elimination 
(Wardemann et al., 2003). Since cloning, expressing, and testing many native VH:VL pairs 
from a large number of B cells is a laborious and expensive task, different modifications 
have been made at the B cell isolation step to minimize the numbers of B cells that need 
to be analyzed.  
As a result of the ease for B cell sorting using FACS, antigen-specific sorting 
technologies have been developed to isolate B cells of interest. Wu et al. demonstrated 
the isolation of B cells that target CD4 binding site in HIV-1 virus (Wu et al., 2010). 
They computationally designed an HIV-1 envelope probe that has all other epitopes 
substituted with those from SIV but an intact CD4 binding site, and a CD4 binding site 
knockout HIV-1 envelope probe, then fished out B cells that showed binding to the 
former but not the latter probe. From these B cells, they isolated the most potent HIV-1 
bnAbs to date by singe-cell RT-PCR. Similar antigen-specific sorting (with single-cell 
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RT-PCR) approaches have been used to isolate antibodies targeting rotavirus (Di Niro et 
al., 2010), transglutaminase-2 (Di Niro et al., 2012), and influenza virus (Whittle et al., 
2014).  
Alternatively, Epstein-Barr Virus (EBV) mediated B cell immortalization has 
been used to interrogate a large number of B cells to identify those secreting antigen-
specific antibodies (Traggiai et al., 2004). Compared to antigen-specific B cell sorting, B 
cell immortalization enables the functional characterization of antibodies (for example, 
neutralization) rather than just binding. Traggiai et al. first reported the improvement of 
EBV immortalization by Toll-like receptor 9 (TLR9) stimulation with CpG DNA or other 
polyclonal stimulants and the subsequent isolation of neutralizing antibodies against 
SARS coronavirus (Traggiai et al., 2004). Antibodies against influenza virus (Corti et al., 
2011), HIV-1 (Corti et al., 2010), dengue virus (de Alwis et al., 2012; Dejnirattisai et al., 
2010), malaria (Tan et al., 2016), Ebola virus (Corti et al., 2016), and Zika virus (Stettler 
et al., 2016) have all been isolated with similar approaches.  
Although there has been much success with this technique, a major limitation of B 
cell immortalization is the restriction to memory B cells, due to the resistance of 
plasmablasts/plasma cells to EBV immortalization. The same limitation also restricts the 
use of antigen-specific B cell sorting, as plasmablasts/plasma cells have very low (none) 
surface BCR expression. The use of plasmablasts/plasma cells for antigen-specific 
antibody isolation was first demonstrated by Wrammert et al., who isolated influenza 
virus specific antibodies from day 7 plasma cells after booster vaccination (Wrammert et 
al., 2008). The success of isolating antigen-specific antibodies from plasmablasts/plasma 
cells heavily depends on the quality of immune response and the time 
plasmablasts/plasma cells are collected. 
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In general, single-cell RT-PCR is a very powerful technique, but it is severely 
limited by being low-throughput, with usually less than 100,000 cells processed per 
experiment, along with the heavy workload and cost with antibody cloning and 
expression. On the other hand, NGS provides a much higher throughput, which enables 
the processing of more than 1,000,000 cells in a single experiment. This allows much 
deeper analysis of antibody repertoires than with single-cell RT-PCR. 
Next-generation Sequencing 
Since its release in 2005, NGS has been used more and more for cellular antibody 
repertoire analysis, as a result of the rapidly increasing throughput and decreasing cost. 
The inherent complexity of antibody repertoires also makes NGS a superior tool for 
interrogation. 
NGS for antibody repertoires usually uses antibody mRNA as templates. From 
isolated B cells, mRNA is extracted after cell lysis, and the VH and VL are amplified 
separately. This pool of VH and VL sequences encoded by different B cells can be 
sequenced on various platforms (the most popular is Illumina). Bioinformatic analysis is 
performed to obtain the antibody sequences in the repertoire (Fig. 1-4). Important 
features of the antibody repertoire, including unique clonotypes, CDR3 length 
distribution, and somatic hypermutation rates can also be obtained. NGS has been used 
for in-depth analysis of antibody repertoires after vaccination (Jiang et al., 2013) and 
natural infection (Doria-Rose et al., 2014; Liao et al., 2013), which provides important 
insights into how B cells respond to pathogens longitudinally (Doria-Rose et al., 2014; 
Liao et al., 2013). It has also been used to interrogate antibody repertoires in neonatals 
and the elderly (Rechavi et al., 2015), which helps to better understand the development 
of B cells. Moreover, the comparison of antibody repertoires in twins by NGS enables the 
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investigation of genetic and environmental effects on antibody repertoire development 
(Wang et al., 2015b). 
The selection of promising high-affinity, antigen-specific antibodies from 
millions of sequences requires special consideration. The most common way is to select 
antibodies within the same lineages as known functional antibodies (for example, HIV-1 
bnAbs) (Zhu et al., 2013a, 2013b). If CDRH3 sequences are available from proteomic 
analysis, they can be used to select antibodies with the same CDRH3 (Lavinder et al., 
2014). However, of millions of sequences obtained from NGS, only a very minor portion 
of them, namely, tens or hundreds can be reconstructed, expressed, and characterized due 
to laborious and expensive gene synthesis and cloning. Likewise, the intrinsically higher 
error rate of NGS compared to that of Sanger sequencing used in single-cell RT-PCR 
makes antibody repertoire analysis nontrivial (Georgiou et al., 2014a). In order to 
distinguish between sequencing errors and true sequence variations, careful experimental 
design and bioinformatic analysis to minimize sequencing errors are critical. Several 
techniques are used to improve NGS accuracy, with barcoding being the most widely 
used (Georgiou et al., 2014b). For sequence analysis and annotation, IMGT (the 
International Immunogenetics Information System) is the most commonly used tool 
(Lefranc et al., 2009). 
The major limitation of NGS is the bulky processing of B cells makes native 
VH:VL pairing lost. Furthermore, only up to hundreds of antibodies can be made with as a 
result of the cost for gene synthesis. In general, these repertoire analysis methods have 
been widely used and shown to identify potent antibodies against complex human 
pathogens, such as HIV-1, Ebola and influenza virus, malaria, and Zika virus (Corti et al., 
2011, 2016; Huang et al., 2012, 2014; Stettler et al., 2016; Tan et al., 2016). 
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Serological antibody repertoire analysis 
Antibodies in the serum are those that protect from pathogens, hence, the 
characterization of serological repertoires is of great importance. Recent advances in 
mass spectrometry have enabled detailed than ever, and accurate deconvolution of 
serological antibody repertoires (Cheung et al., 2012; Wine et al., 2013). Wine et al. and 
Cheung et al. first reported the characterization of rabbit/mouse antibody repertoires with 
liquid chromatography-tandem mass spectrometry after immunization (Cheung et al., 
2012; Wine et al., 2013). Lavinder et al. and Sato et al. then reported the characterization 
of human antibody repertoires after tetanus toxoid and hepatitis B virus vaccination and 
human cytomegalovirus infection (Lavinder et al., 2014; Sato et al., 2012). 
In these cases, antigen-specific antibodies in the serum are enriched by antigen-
affinity capture and digested with pepsin to remove Fc fragments. The Fab fragments are 
then digested with trypsin to produce CDRH3 containing peptides (most informational 
peptides) (Fig. 1-5). These peptides are analyzed by mass spectrometry and mapped back 
to a database of antibody sequences (usually generated by NGS of antibodies isolated 
from B cells collected at the same time with the serum) to retrieve the full-length 
sequences. Promising antibodies are then selected, reconstructed, and assayed. Although 
proteomic analysis of serological antibody repertoires is very powerful, it has to rely on 
the full-length antibody sequence database generated by NGS to predict and infer the 
fragmented peptides. 
ADVANCING HIGH-THROUGHPUT CHARACTERIZATION OF NATIVE ANTIBODY VH:VL 
PAIRS 
As a result of the importance of antibody VH:VL chain pairing, and the major 
limitations of single-cell RT-PCR (low throughput) and NGS (loss of native VH:VL 
pairing), DeKosky et al. developed a high-throughput pairing and sequencing method for 
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native VH:VL pairs, that combines the advantages of single-cell RT-PCR (preservation of 
native VH:VL pairing) and next-generation sequencing (high-throughput) (DeKosky et al., 
2013, 2015) (Fig. 1-6). By sequestering single B cells in micro emulsion droplets, lysing 
the cells and capturing mRNA using oligo(dT) beads, and linking and amplifying 
captured antibody coding sequences in single bead emulsion through RT-PCR, amplicons 
composed of native VH: VL pairs are obtained. Illumina paired end sequencing is used to 
determine antibody sequences in the amplicons. 
Alternatively, Busse et al. used a two-dimensional, bar-coded primer matrix to 
integrate single-cell RT-PCR of VH:VL pairs with NGS  (Busse et al., 2014). After next-
generation sequencing, they were able to recover pairs from up to 50,000 cells. Although 
it can process a lot more B cells than single-cell RT-PCR, the throughput is still low 
compared to that of emulsion based pairing and sequencing. 
Zhu et al. developed a ‘pseudo’ VH:VL pairing method which relies on 
phylogenetic reconstruction for antibody lineage characterization (Zhu et al., 2013a, 
2013b). They first observed the matching patterns of VH and VL phylogenetic trees during 
the co-evolution of HIV-1 virus and bnAbs, then paired VH and VL from the matching 
branches of the phylogenetic trees based on this observation to obtain new bnAbs. This 
phylogenetics based VH:VL pairing is useful for the analysis of antibody repertoires with 
high somatic hypermutation levels. However, unlike the physical linkages between VH 
and VL generated in emulsions, and barcoded PCRs used to retain pairing information, 
there are no real physical linkages produced in phylogenetic pairing, so the VH:VL pairs 
obtained may not exist. 
These high-throughput VH:VL pairing methods greatly expanded the number of 
native antibody pairs that can be obtained in one experiment, but the number of 
antibodies that can be functionally characterized is still very limited. 
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ANTIBODY DISCOVERY AND ENGINEERING 
B cell immortalization 
The most commonly used method for antibody discovery is B cell 
immortalization. Depending on origins of B cells, two different methods can be used.  
Köhler and Milstein first demonstrated B cell immortalization by fusing mouse spleen 
cells with myeloma cells (Kohler and Milstein, 1975). The fused hybridomas can secrete 
antibodies in in vitro culture. Hybridoma fusion has been widely used for antibody 
discovery. In many cases, after immunization of mice with the target antigen, isolation of 
antibody-producing cells, and fusion with myeloma cells, immortalized antibody-
producing cells can be generated and screened to identify those that secrete antigen-
specific antibodies. However, as a result of the low cell viability after fusion, a large 
number of fused cells have to be made to select antigen-specific antibodies. Moreover, as 
a result of the general difficulty of and regulations for human immunization and 
antibody-producing cell isolation, hybridomas are often produced using mouse cells.  
The success for mouse antibody discovery using hybridomas inspired efforts to 
adapt the hybridoma approach for human antibody discovery. However, human B cells 
were found to be more resistant to myeloma fusion than mouse B cells (Traggiai et al., 
2004). As a result, EBV mediated immortalization has been developed (Traggiai et al., 
2004). As discussed for single-cell RT-PCR, EBV mediated human B cell 
immortalization has enabled the isolation of antibodies against many human pathogens 
(Corti et al., 2010, 2011, 2016; Stettler et al., 2016; Tan et al., 2016). 
The development of humanized mouse strains provided easy-to-fuse mouse B 
cells that can produce human antibodies. A few previously developed humanized mouse 
strains had mouse Ig loci replaced with only part of the human Ig loci (Fishwild et al., 
1996; Green et al., 1994; Lonberg et al., 1994; Taylor et al., 1992). Thanks to the 
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development of mouse genetics, transgenic mouse strains with the complete human Ig 
loci integrated into the genome have been reported (Lee et al., 2014; Macdonald et al., 
2014; Murphy et al., 2014). In both reports, bacterial artificial chromosomes that have 
different parts of human IgH, Igκ, and Igλ loci respectively were used to target mouse 
embryonic stem cells iteratively to insert the complete human Ig loci in multiple steps. 
These modified embryonic stem cells were then injected into blastocysts to generate 
transgenic mouse.  
The use of human antibodies identified from humanized mouse strains for 
therapeutics also minimizes the immunogenicity problem. As a result of sequence 
differences between mouse and human antibodies, mouse antibodies could elicit strong 
immune responses in humans (for example, human-anti-mouse antibodies). The 
immunogenicity greatly reduces the efficacy of mouse antibodies for therapeutics. On the 
other hand, human antibodies recovered from humanized mouse strains do not have this 
problem and can thus have maximal efficacy. 
In vitro display technologies 
In addition to B cell immortalization, in vitro selection and screening of antibody 
libraries is also widely used for antibody discovery and engineering (Bradbury et al., 
2011). Among the various techniques for antibody library selection, phage display 
(Winter et al., 1994), E. coli surface display (Mazor et al., 2007), and yeast surface 
display (Chao et al., 2006) are the three most widely used. All three techniques share the 
commonality that they link the antibody genotype to phenotype (binding) by expressing 
and displaying vector encoded antibody variants on the cell surface. 
The antibody libraries used in these selection methods are usually combinatorially 
assembled from naïve, immunized, or synthetic VH and VL. These combinatorial libraries 
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provide rich pools of antibodies to select from to identify high-affinity, antigen-specific 
hits. The selected antibodies can be further optimized for functions. 
With recent advance for protein sequence space sampling algorithms (Kaufmann 
et al., 2010), loop modeling algorithms (Mandell et al., 2009), and the improvement of 
energy functions (Kaufmann et al., 2010), computational protein design is used more and 
more to guide antibody library construction. A commonly used approach for 
computation-guided library design and selection is to first identify promising antibodies 
by computational design and assemble them into an antibody library, then select the best 
hits. The designed antibody usually needs further optimization, which includes 
constructing and selecting error-prone or site-directed libraries (Lapidoth et al., 2015). 
In phage display, antibody fragments (usually scFv is used) are fused with phage 
coat proteins (for example, pIII of M13 phage), and displayed on the surface of phages. 
By panning these antibody-displaying phages toward target antigens, antigen-specific 
antibodies can be selected. Phage display has played an important role in mouse antibody 
humanization. 
Similarly, in E. coli display, antibody fragments are covalently anchored on the 
inner membrane. After spheroplasting, these antibody fragments can be screened with 
desired antigens. 
In yeast display, scFv variants are displayed on the cell surface as fusion proteins 
with Aga2, which is covalently linked to Aga1 (Boder and Wittrup, 1997; Chao et al., 
2006). After staining with fluorescently labeled antigens, cells carrying variants that 
possess better binding properties will have higher fluorescence, and can then be sorted 
using FACS. The use of FACS permits high-throughput screening of very large antibody 
libraries. 
 19 
Compared to phage and E. coli display, yeast surface display is a eukaryotic 
system that better mimics the native mammalian conditions under which the antibodies 
express, fold, and exert their functions. Moreover, by using 2-color FACS, it allows 
normalization of binding signal with antibody display levels (Boder and Wittrup, 1997). 
This prevents the recovery of antibodies that bind tighter as a result of higher expression 
level instead of improved affinity. 
A major limitation of in vitro antibody library screening is the non-cognate (non-
native) pairing of VH and VL in the combinatorial libraries may result in many problems 
for downstream development (Liu et al., 2014; Ponsel et al., 2011; Tiller et al., 2013; 
Wang et al., 2014; Wörn and Plückthun, 2001; Xu et al., 2013). Biophysical properties of 
these non-natively paired antibodies are sometimes mediocre (Liu et al., 2014; Ponsel et 
al., 2011; Tiller et al., 2013; Wang et al., 2014; Wörn and Plückthun, 2001; Xu et al., 
2013), which requires extensive improvement for use as drugs. Moreover, an scFv cannot 
be used directly under most circumstances and would need to be reformatted to a Fab 
format for structural stability (Quintero-Hernández et al., 2007).  
Another limitation of in vitro antibody library screening is it only selects for  
binding capacity. After high-affinity antibodies are obtained, functional assays such as 
neutralization still need to be performed to identify those that not only bind, but also exert 
desired functions. In contrast, in B cell immortalization, functional assays can be 
performed with secreted antibodies, which allows direct identification of antibodies that 
both bind and function as expected. 
The recent report of function-based selection for combinatorial libraries using a 
mammalian autocrine system by Lerner and colleagues demonstrates the progress toward  
(Xie et al., 2013). The combinatorial antibody libraries were first polished by phage 
display to enrich target binders, then the enriched libraries were transfected into 
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mammalian cells, which expressed antibodies either in the cytoplasm or on the surface. 
By carefully designing and performing selection (for example, cell proliferation or cell 
death), antibodies with rare functions (for example, cell death prevention, stem cell 
transdifferentiation, tumor cell reprogramming) were selected. This is the first 
demonstration of functional selection of antibody libraries rather than just binding. 
SIGNIFICANCE OF HIGH-THROUGHPUT ANTIBODY REPERTOIRE ANALYSIS AND 
ANTIBODY DISCOVERY 
As a result of their unique features, including high specificity, affinity, stability, 
and their ability to link adaptive immunity to innate immunity, antibodies have been used 
extensively in clinics. For example, monoclonal antibodies (mAbs) based treatment has 
been successfully developed for cancers (including leukemia, lymphoma, and breast 
cancer), graft-versus-host diseases, autoimmune diseases (including systemic lupus 
erythematosus and rheumatoid arthritis), and infectious diseases (RSV and Ebola) (Chan 
and Carter, 2010; Topalian et al., 2016). The year-by-year increasing sale of antibody 
drugs highlights the need of more antibodies for disease treatment and novel techniques 
for rapid high-throughput identification of promising antibodies. 
Antibodies are also widely used in research. Western blots, flow cytometry, and 
chromatin immunoprecipitation are just three of many techniques where antibodies are 
essential. The variable performance of different antibodies and lack of antibodies for 
some targets highlight the need for facile discovery of more antibodies for research use. 
Both traditional antibody discovery and engineering methods and antibody 
repertoire characterization techniques are widely used for novel antibody identification. 
Trastuzumab (HER2 targeting), Rituximab (CD20 targeting), Cetuximab (EGFR 
targeting), Ipilimumab (CTLA-4 targeting) and Nivilomab (PD-1 targeting) are a few 
examples of FDA approved antibodies identified by traditional antibody discovery and 
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engineering, while VRC01 and 3BNC117 (HIV-1 CD4 binding site targeting) are two 
examples of repertoire analysis identified antibodies that are in clinical trials (Scheid et 
al., 2011; Wu et al., 2010). 
Furthermore, antibody repertoire analysis can help vaccine design to elicit more 
robust immune responses. By analyzing a large number of antibodies generated after 
infection or vaccination, the dominant and protective (sub)-dominant epitopes that are 
recognized by these antibodies can be identified. Then stable, immunogenic antigens can 
be rationally designed and engineered to display protective (sub)-dominant epitopes only 
on the protein surface. For some chronic, highly mutating virus infections, the 
longitudinal analysis of antibody repertoires together with analysis of the co-evolving 
virus at different times after infection can provide clues about how a virus can evade 
antibody recognition, and how antibodies go through germinal center reactions to 
recognize constantly mutating viral variants (Doria-Rose et al., 2014; Liao et al., 2013). 
With this longitudinal information, Jardine et al. developed stepwise vaccines to mimic 
the mutating HIV-1 virus for the priming naïve B cells that express predicted germline 
BCRs and the boosting of these selected B cells for affinity maturation to recognize the 
native virus (Briney et al., 2016; Escolano et al., 2016). 
Although many technologies have been developed for antibody discovery and 
repertoire analysis, and a lot of success has been achieved, a high-throughput technology 
that enables native antibody repertoire analysis and antibody discovery at single cell level 
has yet to be fully realized. Moreover, the development of protein therapeutics other than 




































Figure 1-2: Structure of a typical human IgG showing different features in the molecule 







































Figure 1-4: NGS workflow for antibody repertoire analysis. 
(a) Isolation of B cell populations of interest. (b) Cell lysis and bulk amplification of VH 

















Figure 1-5: Proteomic workflow for serum antibody repertoire analysis. 
(a) Serum antibodies are pooled by protein A purification. (b) Antigen-specific antibodies 
are purified by antigen-affinity chromatography. (c) After protease digestion, peptides are 














Figure 1-6: High-throughput VH:VL pairing workflow.  
(a) Isolated B cells are deposited into 125 pL wells on PDMS slides that also contain 
poly(dT) beads. Cells are lysed in situ and mRNA is captured on the poly(dT) beads. (b) 
The poly(dT) beads are emulsified and VH:VL amplicons are generated following reverse 
transcription and overlap extension PCR. (c) VH:VL amplicons are sequenced using 























Chapter 2: Facile Discovery of a Diverse Panel of Anti-Ebola Virus 
Antibodies by Immune Repertoire Mining1 
The ongoing evolution of Ebolaviruses poses significant challenges to the 
development of immunodiagnostics for detecting emergent viral variants. There is a 
critical need for the discovery of monoclonal antibodies with distinct affinities and 
specificities for different Ebolaviruses. We developed an efficient technology for the 
rapid discovery of a plethora of antigen-specific monoclonal antibodies from immunized 
animals by mining the VH:VL paired antibody repertoire encoded by highly expanded B 
cells in the draining popliteal lymph node (PLN). This approach requires neither 
screening nor selection for antigen-binding. Specifically we show that mouse 
immunization with Ebola VLPs gives rise to a highly polarized antibody repertoire in 
CD138+ antibody-secreting cells within the PLN. All highly expanded antibody clones 
(7/7 distinct clones/animal) were expressed recombinantly, and shown to recognize the 
VLPs used for immunization. Using this approach we obtained diverse panels of 
antibodies including: (i) antibodies with high affinity towards GP; (ii) antibodies which 
bound Ebola VLP Kissidougou-C15, the strain circulating in the recent West African 
outbreak; (iii) non-GP binding antibodies that recognize wild type Sudan or Bundibugyo 
viruses that have 39% and 37% sequence divergence from Ebola virus, respectively and 
(iv) antibodies to the Reston virus GP for which no antibodies have been reported. 
                                                
1This chapter is reproduced with minor modifications from its initial publication: 
Wang, B., Kluwe, C.A., Lungu, O.I., DeKosky, B.J., Kerr, S.A., Johnson, E.L., Jung, J., Rezigh, A.B., 
Carroll, S.M., Reyes, A.N., Bentz, J.R., Villanueva, I., Altman, A.L., Davey, R.A., Ellington, A.D., 
Georgiou, G. (2015). Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune 




Ebolaviruses are negative-sense RNA filamentous viruses that cause very high 
morbidity and mortality (Bowen et al., 1977). Host cell entry is mediated first by the 
attachment of the heavily glycosylated glycoprotein (GP) on the viral envelope to the 
host cell encoded T-cell immunoglobulin and mucin domain 1 (TIM-1) (Kondratowicz et 
al., 2011). Following cathepsin cleavage in the lysosome, GP mediates cellular entry by 
binding the host cell encoded Niemann-Pick C1 (NPC1) (Carette et al., 2011). Five 
antigenically distinct ebolaviruses exhibiting 35-45% genome sequence divergence have 
been discovered (Towner et al., 2008): Ebola virus (abbreviated as EBOV, formerly 
designated as Zaire ebolavirus); Sudan virus (SUDV); Bundibugyo virus (BDBV); 
Reston virus (RESTV, for which no zoonotic infections have been reported to date) 
(Miranda and Miranda, 2011); and Taï Forest virus (TAFV, one incident of human 
infection) (Le Guenno et al., 1995). The recent EBOV outbreak in West Africa, centered 
in Guinea, Sierra Leone, and Liberia with isolated outbreaks in Nigeria and Mali, was the 
largest ever with a mortality rate estimated at 70% of recorded definitive clinical 
outcomes (http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/index.html) (Team, 
2014). Phylogenetic comparison of isolates from the recent outbreak (Baize et al., 2014) 
with 20 Ebolavirus genomes from earlier outbreaks suggested that the 2014 West African 
virus likely spread from central Africa within the past decade, having diverged from a 
common ancestor around 2004 (Gire et al., 2014). The five Ebolavirus species have 
varying rates of molecular evolution, with the highest of 8.21x10-4 nucleotide 
substitutions/site/year for Reston virus (Carroll et al., 2013). The ongoing evolution of 
Ebolaviruses poses significant challenges to the development of immunodiagnostics. 
Specifically, there is a critical need for the discovery of panels of monoclonal antibodies 
with distinct affinities and specificities for different Ebolaviruses. 
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Antibodies to EBOV and SUDV have been produced from hybridomas (Dias et 
al., 2011; Qiu et al., 2011);  by in vitro screening of synthetic scFv libraries (Chen et al., 
2014; Koellhoffer et al., 2012), and from human immune antibody libraries constructed 
from infected individuals (Maruyama et al., 1999). However additional monoclonal 
antibodies to Ebolaviruses are urgently needed both for diagnostic purposes and as 
therapeutics (Parren et al., 2002; Qiu et al., 2014). Specifically, the generation of 
diagnostic antibodies to Ebolaviruses is complicated by the structural complexity of the 
GP, which is heavily glycosylated in a host cell-specific manner (Heinz Feldmann, Stuart 
T. Nichol, Hans-Dieter Klenk, Clarence J. Peters, 1994; Lin et al., 2003) and subjected to 
proteolytic cleavage during entry (Hood et al., 2010), as well as by the sequence diversity 
of the Ebolaviruses. Finally, characterization of useful antibodies to Ebolaviruses is 
limited by the safety concerns associated with handling the live virus. 
Antibody discovery has relied either on the immortalization (Kohler and Milstein, 
1975) or cloning of antibodies isolated from individual B cells obtained from an antigen-
challenged host (Corti et al., 2011; Ghosh and Campbell, 1986; Lane and Koprowski, 
1982; Reddy et al., 2010; Saggy et al., 2012; Wu et al., 2010) or, alternatively, on the in 
vitro isolation from combinatorial libraries using a variety of screening techniques 
(Bradbury et al., 2011). The current collection of antibody technologies is predicated on 
the isolation of clones that display high antigen binding. However, animal immunization 
induces the stimulation and expansion of a highly diverse population of B cells encoding 
an antibody repertoire with a wide range of antibody affinities (Reddy et al., 2010; Saggy 
et al., 2012). Antibodies with low affinity nonetheless may exhibit other highly desirable 
properties, including broad cross-reactivity or heteroclitic specificity, i.e. stronger 
binding reaction to a different antigen other than the one used for immunization (Ghosh 
and Campbell, 1986; Lane and Koprowski, 1982; Van Regenmortel, 2014). 
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Unfortunately, there is no straightforward way to identify such interesting antibodies. For 
example, while the isolation of antibodies that bind to multiple antigens (e.g. to different 
flu hemagglutinins) or that neutralize rapidly evolving pathogens such as HIV-1 or flu 
has been accomplished by B cell cloning, the process typically requires the screening of 
many thousands of B cells and therefore is very laborious and expensive (Corti et al., 
2011; Walker et al., 2009, 2011; Wu et al., 2010). 
In order to satisfy the need for a wider variety of antibodies to Ebolaviruses, we 
developed a novel approach to comprehensively mine the full suite of antibody diversity, 
shaped by in vivo selective mechanisms and generated within the boundary of reactive 
secondary lymphoid tissues in immunized animals. We reasoned that antibodies encoded 
by antigen-stimulated B cells that had undergone the greatest degree of expansion within 
the confinement of a secondary lymphoid organ are most likely to display desirable 
antigen recognition properties including heteroclite recognition of diverse Ebolaviruses. 
Briefly, mice were first immunized in the footpad with Ebola virus-like particles (VLPs).  
Footpad immunization triggers a strong and highly-focused immune reaction in the PLN, 
especially for particles <40 nm such as VLPs32. Antigen experienced, CD138+ B cells 
(plasmablasts) from the PLN were isolated and the natively paired VH:VL repertoire 
encoded by these cells was determined by NextGen sequencing33. Antibodies 
corresponding to the highest frequency VH:VL pairs, and thus likely arising from the most 
clonally expanded and highly-transcribing CD138+ B cells within the PLN, were 
expressed recombinantly and their binding properties were characterized in detail. In each 
of two mice tested, 7/7 antibodies encoded by the highest frequency antigen-draining 
PLN plasmablast sequences recognized the antigen (Ebola VLPs) with several binding to 
recombinant GPs with up to nM affinities. Interestingly, even though animals had been 
immunized with EBOV VLPs, mining of the expanded native B cell repertoire within the 
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PLN resulted in antibodies that also recognized SUDV and BDBV. In a separate 
experiment we also employed this technique to generate the first RESTV GP-specific 
antibodies. Thus, the antibodies reported here collectively constitute a panel of reagents 
for the detection of most Ebolaviruses. 
RESULTS 
Immunization of the PLN yields antigen-specific antibodies 
Fig. 2-1 summarizes our approach for mining the antibody repertoire encoded by 
the most highly expanded, antigen-experienced B cells following antigen stimulation. 
Footpad immunization leads to a strong inflammatory response in the draining popliteal 
lymph node (Fig. 2-1a). Unlike lymph nodes that drain sites of frequent extracorporeal 
interaction (e.g. the oral cavity or lungs), the germinal centers of the popliteal lymph 
node are normally relatively unstimulated (Kamala, 2007). Footpad immunization results 
in a marked increase in cellularity in the ipsilateral popliteal lymph node relative to the 
unstimulated contralateral lymph node (Gleichmann, 1981; Ravel and Descotes, 2005), 
and a large fraction of the constituent antibody-secreting B cells were expected to be 
antigen-specific. 
Ebola VLPs were produced by co-transfection of HEK293FT cells with plasmids 
encoding the three major virus structural proteins: nucleoprotein (NP), VP40 and GP of 
the EBOV Mayinga strain and were purified by sucrose density centrifugation. Electron 
microscopy and gel staining confirmed that the VLPs displayed a morphology and 
consistency characteristic of EBOV virions. Three mice were immunized with Ebola 
VLPs in emulsified adjuvant in the left hind footpad, followed by boost immunization in 
the lateral hock to minimize pain and discomfort. An anti-VLP titer of >1:104 was 
observed after the second boost (Fig. 2-2a) in all three mice, and two mice (denoted as 
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ZM1 and ZM2) were chosen for further analysis. A final boost was administered and 6 
days later the popliteal lymph nodes were extracted. As expected, the ispilateral PLN was 
observed to be hypertrophic (Fig. 2-2b). 
CD45R-CD19-CD138+ antibody secreting B cells were enriched by magnetic 
sorting and the paired VH:VL repertoire from single cells was determined following 
sequestration of the cells into 125 pL wells on PDMS slides (DeKosky et al., 2013) (Fig. 
2-1b). Approximately 1x105 CD45R-CD19-CD138+ plasmablasts were isolated by 
magnetic sorting, of which 2.5-3.5x104 cells were processed to create natively paired 
VH:VL amplicons. Linked VH:VL amplicons of approximately 850 bp were generated and 
then sequenced using Illumina MiSeq technology (Fig. 2-1c). High quality reads were 
clustered based on the CDRH3:CDRL3 sequences (Fig. 2-1d). 
The PLN plasmablast IgG repertoire elicited by immunization with EBOV 
283 and 333 unique VH:VL pairs (represented by ≥2 sequence reads per pair each), 
comprising the PLN plasmablast repertoires were identified in mouse ZM1 and mouse 
ZM2,  respectively. The repertoires from both Ebola VLPs immunized mice investigated 
were heavily skewed, with the top ten most abundant VH:VL pairs representing 53.9% and 
48.4% of the total sequence counts in each mouse, respectively (Fig. 2-3a). We observed 
a strong bias in germline V-gene usage in immunized mice (Fig. 2-3b,c). Biased usage of 
IGHV subgroups 1–3 and 5 (Kaushik and Lim, 1996; Lu et al., 2014), as well as IGKV1, 
3, 4 and 6 have been previously observed in the repertoires of unimmunized mice (Lu et 
al., 2014). Likewise, in Ebola VLPs immunized mice, IGHV1, IGHV5, as well as 
IGKV1, IGKV3, IGKV4, and IGKV6 heavy and light V genes were most strongly 
represented. Importantly, however, the IGHV8, IGHV14, and IGKV5 families were also 
strongly overrepresented in both mice immunized with EBOV VLPs. The enrichment of 
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IGHV8 in the plasmablast repertoire from PLN of Ebola VLPs immunized animals is 
particularly noteworthy as this germline family is expressed at a very low level in mice 
(Kaushik and Lim, 1996; Lu et al., 2014) and additionally it was shown to be utilized at 
very low frequencies in CD138+ lymphocytes from animals immunized with various 
other antigens (Reddy et al., 2010). 
The repertoire of Ebola VLPs immunized mice displayed an average CDRH3 
length distribution similar to that observed in CD138+ repertoires previously reported 
(Reddy et al., 2010), although there was a slight skewing toward shorter CDRH3 lengths. 
Shorter CDRH3s are commonly found among antibodies that bind carbohydrates and 
thus the skewing observed here likewise may have reflected the elicitation of antibodies 
to the glycan component of the heavily glycosylated GP (Schoonbroodt et al., 2008). The 
plasmablast repertoire from EBOV VLPs immunized mice displayed a higher level of 
somatic hypermutation level in the framework 3 (FR3) heavy chain region compared to 
plasmablast repertoires reported for mice hyperimmunized with various other protein 
antigens (Reddy et al., 2010). 
Construction and characterization of anti-EBOV VLP antibodies 
The CDRH3 and CDRL3 amino acid sequences of the 7 highest frequency VH:VL 
clonotypes from each mouse, together with the respective V(D)J gene segments are listed 
in Table 2-1. Antibody genes for these 14 most prevalent VH:VL antibody clonotypes 
were synthesized and cloned as mouse V region-human constant domain chimeric 
antibodies, expressed in HEK293 cells, and characterized for antigen binding (Fig. 2-
1e,f). KZ52, a very well characterized Ebola virus recognizing antibody isolated from a 
survivor of the 1995 Kikwit outbreak (Lee et al., 2008; Maruyama et al., 1999), was 
expressed as a positive control. All 14 antibodies gave an ELISA signal above 
 35 
background on plates coated with the immunizing antigen, i.e. EBOV (Mayinga strain) 
VLPs (Fig. 2-4a). ELISA titer analysis revealed that the majority of the antibodies bound 
VLPs at a titer >1:1,000. Interestingly, the ELISA signals did not correlate with the 
frequency of the respective antibodies in the PLN CD138+ repertoire. 
5/14 antibodies recognized the recombinant uncleaved form of the EBOV 
Mayinga strain GP (Fig. 2-4b). One antibody bound to GP with a single-digit nM 
equilibrium dissociation constant (ZM1.3, KD=7.7 nM), as determined by SPR analysis 
(Table 2-2, Fig. 2-5), while two others (ZM1.1 and ZM2.1) exhibited KD values in the 10 
nM range. Finally, 2/5 GP specific IgGs, ZM1.2 and ZM1.6, exhibited lower affinities 
(KD =156 and 635 nM, respectively (Table 2-2, Fig. 2-5)), consistent with the lower titer 
of those antibodies for Ebola VLPs. 
The three highest affinity, EBOV GP-specific antibodies (ZM1.1, ZM1.3 and 
ZM2.1) were tested for binding to VLPs encoding GPs from Ebola strains isolated from 
two different outbreaks: 034-KS (Democratic Republic of Congo, 2008, NCBI Accession 
number HQ613402) and Kissidougou-C15 (Kissidougou, Guinea, 2014, NCBI Accession 
number KJ660346). Both ZM1.3 and ZM2.1 showed higher binding to Ebola 034-KS and 
Kissidougou-C15 VLPs than the well-studied KZ52 antibody (KD for purified Mayinga 
GP=1.55 nM). We observed that KZ52 failed to recognize VLPs containing a Mayinga 
GP N550K variant in which Arg 550 residue was replaced with Lys, a mutation observed 
in Marburg GP (Manicassamy et al., 2007), while ZM1.1, ZM1.3 and ZM2.1 were still 
able to bind the Mayinga GP N550K variant.  This finding indicates that ZM1.1, ZM1.3 
and ZM2.1 likely recognize a different epitope than KZ52. Interestingly, ZM1.3 
displayed heteroclitic specificity in that it bound better to EBOV 034-KS and 
Kissidougou-C15 VLPs than to the immunization Mayinga strain VLPs (EC50 of 0.334 
nM and 0.39 nM, respectively compared to 1.7 nM for Mayinga VLPs).  These antibodies 
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also bound to live wild type Ebola virus, indicating that they should be useful for 
developing diagnostic assays against primary biological samples. 
Finally, encouraged by the results detailed above, we used the strategy described 
in Fig. 2-1 to develop antibodies that recognized Reston Ebola virus (RESTV, Reston, 
1996, NCBI Accession number AB050936), an Ebolavirus for which no anti-GP 
monoclonal antibodies are available. RESTV VLPs were generated, mice were 
immunized as above, and the repertoire encoded by PLN plasmablasts was determined. 
We identified three antibodies designated RM2.4, RM3.2, and RM3.3 that bound to both 
RESTV VLPs as well as to RESTV recombinant GP (Fig. 2-6). 
Diagnostic utility of non-GP binding antibodies 
While 9/14 anti-EBOV VLP antibodies did not show binding to the GP and thus 
presumably recognized other VLP proteins (NP, VP40) they nonetheless are of diagnostic 
utility. Specifically, in addition to binding to EBOV Mayinga VLPs, antibodies ZM1.4, 
ZM1.7, ZM2.2, ZM2.3, ZM2.5, and ZM2.6 displayed measurable binding to Bundibugyo 
Virus (BDBV, Bundibugyo, 2007, NCBI Accession number FJ217161), while ZM1.7, 
ZM2.2, ZM2.5, and ZM2.6 also showed binding activity to Sudan Virus (SUDV, Gulu, 
2000, NCBI Accession number AY729654) (Representative ELISA data is shown in Fig. 
2-7a-c). Thus, antibodies elicited by immunization with EBOV VLPs bound differentially 
to phylogenetically diverse variants. 
DISCUSSION 
Here we report a facile and rapid approach for generating large panels of distinct 
monoclonal antibodies that, unlike existing antibody discovery platforms, does not rely 
on screening for antigen binding; and further describe application of this approach by 
developing panels of diagnostic antibodies for Ebola virus strains. We found that in 
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multiple animals immunized with EBOV or RESTV VLPs, the repertoire of CD138+ 
plasmablasts in the draining PLN was dominated by highly expanded, antigen-specific, 
antibody sequences. We find that these highly expanded sequences include antibodies 
that display high affinity to GP, bind to live, wild-type virus and, somewhat surprisingly, 
display diverse specificities to VLPs from different Ebolaviruses. Among the antibodies 
isolated, six recognized live Bundibugyo or both Bundibugyo and Sudan viruses in 
addition to EBOV. These results demonstrate the power of mining the antibody repertoire 
of highly expanded B cells after immunization for discovery of antibodies with 
interesting properties. 
The ability to isolate 7 (and possibly more) distinct antibodies with very different 
CDR3 sequences per animal as well as a much larger number of somatic variants whose 
sequences are also available in the VH:VL sequence database provides a rich source of 
antibodies for practical purposes. Undoubtedly, many PLN B cells encoding antigen-
specific antibodies are likely to have been subject to more limited expansion and thus are 
present at a lower abundance within the repertoire. However, such medium or low 
abundance antibody sequences within the repertoire are present at comparable levels to 
those elicited by environmental stimuli and thus recognizing unrelated antigens.  
Therefore the low abundance antigen-specific antibody sequences in the repertoire cannot 
be identified directly without significant additional effort. 
The method we have pioneered should prove particularly useful for the facile 
development of diagnostic (and possibly therapeutic) antibodies. Starting from antibody-
secreting B cells, it took us only 3 weeks to produce and characterize a diverse set of 
antigen-specific antibodies with a variety of useful specificities. This method should be 
particularly valuable for assessing and combating fast spreading pandemics. 
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In case of rapidly spreading emerging diseases such as Ebola, rapid and robust 
diagnostics are critical for treatment and disease control. For Ebola in particular, 
validated PCR based assays suitable for field work in third world countries are not 
available. Highly sensitive antibody based immunodiagnostics are extremely important 
and easy to implement (Towner et al., 2004). However, a dearth of monoclonal 
antibodies for emergent Ebolaviruses limits the ability to use antigen-capture 
technologies for viral identification of early-stage infections. The panel of antibodies 
identified and characterized here should be useful for diagnostic applications including 
discriminating SUDV, BDBV, and EBOV. By using multiplex immunoassay platforms 
such as the Luminex MagPlex® technology, it should be possible to multiplex up to 50 
different antibodies with varying specificities for a broad range of epitopes, thus ensuring 
wide coverage of Ebolaviruses variants. Studies to incorporate the antibodies we have 
described here onto the Luminex MagPlex® diagnostic platform for field applications are 
on-going. 
METHODS 
VLP Production and Characterization 
VLPs were produced by co-transfection of HEK293FT (Invitrogen) cells with 
plasmids encoding the three major virus structural proteins, NP, VP40 and GP. All open 
reading frames for virus structural proteins were obtained from NCBI and were codon 
optimized for mammalian cell expression using Gene Designer (DNA 2.0), synthesized 
(Epoch Life Science) and inserted into either pcDNA3 (for Ebola GP) or pCAGGS (all 
other genes) mammalian expression plasmids. Sequences of the structural protein ORFs 
were verified and are available upon request to R. A. D. Cells were transfected with each 
of 5 mg NP, 5 mg VP40 and 1 mg GP encoding plasmids by the calcium chloride/BES 
 39 
transfection method. After 24 h cells were washed with DMEM, which was replaced with 
DMEM containing 10% (v/v) FBS. After an additional 24 h, the culture supernatant was 
collected and clarified by centrifugation at 3750 rpm for 30 min at 4oC to remove cell 
debris. The supernatants were then overlaid onto a 5 mL 20% (w/v) sucrose cushion in 20 
mM NaCl, 20 mM HEPES, pH 7.4 in an SW28 ultracentrifuge tube (Beckman). The 
VLPs were then pelleted by centrifugation at 28,000 rpm for 2 h at 4oC in an SW28 rotor. 
To further purify VLPs, the pellet was resuspended in PBS and overlaid onto a 20 to 60% 
sucrose step gradient (5% increments) in 20 mM NaCl, 20 mM HEPES, pH 7.4 in a 
SW55 rotor tube (Beckman). The gradient was centrifuged at 38,000 rpm for 2 h at 4oC 
after which an opaque band corresponding to VLPs was visible. Fractions were collected 
corresponding to the band as well as directly above and below it and analyzed by SDS-
PAGE, staining for total protein with Krypton stain (Thermo Scientific) as well as 
immunoblotting. The middle fraction containing the peak of the VLPs was stored at -
80°C until required. For immunoblotting, proteins were transferred to nitrocellulose 
membranes and stained using broadly reactive polyclonal antibodies against GP (gift 
from Dr. Andrew Hayhurst, Texas Biomedical Research Inst.), VP40 (gift from Dr. 
Ricardo Carrion, Texas Biomedical Research Inst.) or NP (IBT Bioservices). A specific 
monoclonal antibody against Zaire Ebolavirus GP was also used (4F3, IBT Bioservices). 
Appropriate secondary antibodies were purchased from LiCor Biosciences. Blots were 
imaged using a LiCor Odyssey SA imager. Electron microscopy of VLPs was performed 
at the University of Texas Health Sciences Center, San Antionio, Department of 
Pathology electron microscopy facility. VLPs were adhered to copper grids. The samples 
were fixed in glutaraldehyde and osmium tetroxide was used as contrast agent. Images 
were captured on a Philips 208S digital imaging electron transmission microscope. 
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Immunizations and Serum Titer Determination 
The study was approved by the University of Texas Institutional Animal Care and 
Use Committee (AUP-2013-00015). All animal experiments were carried out in 
accordance with the approved protocol. VLPs in PBS pH 7.4 were emulsified in a 1:1 
ratio with TiterMax Gold adjuvant (Sigma). For footpad immunizations, 20 µL 
(containing a total of 5 mg VLPs) antigen/adjuvant mixture was injected into the 
subcutaneous space of three BALB/c mice; for lateral hock injections, up to 50 µL was 
injected into the subcutaneous space just proximal to the lateral aspect of the ankle. Mice 
were immunized at footpad on day 0 for primary immunizations, and in the lateral hock 
on days 21, 35, and 77 for secondary immunizations. At days 10, 28, and 42 mice were 
bled for titration of the antigen-specific response. In order to determine serum antibody 
titer, mice were restrained in a tube restrainer, the tail wiped with isopropyl alcohol, and 
small incisions made with a fresh scalpel blade to nick the tail vein.  20-50 µL blood was 
obtained and allowed to coagulate at room temperature (RT) for 30 min, followed by 
centrifugation at 13,000 g for 15 min to pellet the clot.  The serum was then used for 
ELISA assays. High binding ELISA plates (Corning) were coated overnight (O/N) at 4°C 
with 50 µL of 4 µg/mL Zaire Ebolavirus VLPs in PBS pH 7.4.  Antigen solution was 
decanted and plates were then blocked at RT for 2 h in 2% milk (w/v) in PBS.  Blocking 
solution was then decanted and plates were then incubated with 50 µL of serum diluted 
three-fold from 1:100 to 1:218,700 in 2% milk (w/v) in PBS for 1 h.  Plates were then 
aspirated and washed 3 times with PBS containing 0.05% tween-20 (PBST), then 
incubated with 50 µL of 1:5000 diluted goat anti-mouse HRP secondary antibody 
(Jackson ImmunoResearch) for 1 h.  Plates were washed 3 times with PBST, and 
incubated with 50 µL TMB-Ultra (Thermo Scientific) for 15 min.  The reaction was 
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quenched with 50 µL 2 M H2SO4 and absorbance was read at 450 nm on a Tecan M200 
plate reader. 
Tissue Collection, Cell Isolation, and Subtype Purification 
After determination of significant titer for Ebolavirus VLPs (signal evident above 
background at dilution > 1:10,000), mice were administered a final boost at day 77, and 
lymph nodes were collected 6 days later. For lymph nodes collection, mice were injected 
with 5-10 µL of 2% Evans Blue (Sigma) in PBS into the footpad.  30 min post-injection, 
mice were sacrificed by carbon dioxide asphyxiation followed by cervical dislocation.  
The skin and fur around the leg was removed to reveal the blue-stained popliteal lymph 
node (Fig. 2-1a), located just behind the knee. The lymph node was isolated and and 
stored in PBS pH 7.4 supplemented with 0.1% (w/v) BSA, 2 mM EDTA in a 6-well plate 
(Corning). Lymph node was homogenized by mechanical disruption using two 18G 
needles. The cells were then passed through a 70 μm cell strainer (Corning), with 
additional disruption using the plunger from a 3 mL syringe to aid passage of single cells. 
Cells were then spun down at 500 g for 10 min in a swinging bucket rotor. The cell 
pellets were then resuspended in 2 mL red blood cell lysis buffer (155 mM NH4Cl, 12 
mM NaHCO3, 0.1 mM EDTA) and incubated at room temperature for 3.5 min.  The lysis 
reaction was quenched by adding 20 mL PBS buffer followed by centrifugation at 500 g 
for 10 min at RT. Cells were washed again with 5 mL PBS buffer and resuspended in a 
final volume of 1 mL buffer. Plasma cells were then isolated using the Miltenyi Plasma 
Cell Isolation kit (Miltenyi Biotec). Briefly, non-plasma cells were depleted by magnetic 
labeling of CD49b and CD45R followed by enrichment of magnetically-labeled CD138+ 
cells.  CD45R is a pan-B cell marker expressed on naïve and activated B lymphocytes, 
but not on antibody-secreting cells. Conversely, CD138 is expressed on pre-B and 
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immature B-lymphocytes in the bone marrow, lost upon emigration into secondary 
lymphoid tissues, and re-expressed upon differentiation into plasma cells. 
Single Cell VH:VL Sequencing 
Sorted cells were analyzed by single B cell VH:VL sequencing as previously 
described33.  Briefly, single cells were isolated into 125 pL wells printed in PDMS along 
with poly(dT) conjugated magnetic beads.  Cell lysis and capture of mRNA was 
performed in situ, and beads were collected and emulsified to serve as template for 
emulsion overlap extension RT-PCR. A follow-up nested PCR resulted in 850 bp 
amplicons containing linked genetic information for VH and VL genes.  850 bp amplicons 
were analyzed using the Illumina MiSeq 2x250 platform.  VH and VL genes were 
amplified separately for full-length VH and VL analysis using the Illumina MiSeq 
platform as previously described (DeKosky et al., 2013). 
Sequence Analysis 
Raw MiSeq data was analyzed as previously described (DeKosky et al., 2013).  
Briefly, raw data were filtered for a minimum Phred quality score of 20 over 50% of 
nucleotides to ensure high read quality in the CDR3 regions of heavy and light genes.  
Sequence data were submitted to the IMGT information system for V-D-J germline gene 
mapping.  Sequences were filtered for in-frame V-D-J junctions and VH:VL pairs were 
compiled by exact CDRH3:CDRL3 nucleotide match. CDRH3 junction nucleotide 
sequences were clustered to 96% identity and resulting clusters with >=2 VH:VL reads 
were ranked by MiSeq read counts (DeKosky et al., 2013). Due to read length limitations 
of current next-generation sequencing technology, the complete VH and VL genes were 
also sequenced and analyzed separately.  Full-length VH and VL genes were filtered for a 
minimum Phred quality score of 20 over 50% of nucleotides and were compiled by 
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CDRH3 and CDRL3 exact nucleotide match.  Consensus sequences of VH and VL genes 
(i.e. from all reads passing quality filters and that contained exact matches to the 
CDRH3:CDRL3 pair of interest) were used for antibody gene synthesis, expression, and 
in vitro analysis (DeKosky et al., 2013). 
IgG Synthesis, Expression, and Purification 
Consensus VH and VL genes were designed and purchased as gBlocks (Integrated 
DNA Technologies) and cloned into the pcDNA3.4 vector (Invitrogen) containing 
Oryctolagus cuniculus IgG leader peptide as fusions to human IgG1 and kappa constant 
regions, respectively. Sequences of both the heavy and the light chain for each antibody 
variant were confirmed by Sanger sequencing. Plasmids for each antibody variant were 
transfected into Expi293 cells (Invitrogen) at a 1:3 heavy:light ratio.  After incubating at 
37°C with 8% CO2 at 125 rpm for 6 days, the supernatant containing secreted antibodies 
was collected by centrifugation at 500 g for 15 min at 25°C. Supernatant was passed over 
a column of 0.5 mL Protein A agarose resin (Thermo Scientific) three times to ensure 
efficient binding. After washing with 20 column volumes of PBS, antibodies were eluted 
with 3 mL 100 mM citric acid pH 3.0 and immediately neutralized with 500 µL 1M Tris 
pH 8.0. Antibodies were buffer exchanged into PBS, pH 7.4 utilizing Amicon Ultra-30 
centrifugal spin columns (Millipore) for storage and subsequent use. 
ELISA 
Costar 96-well ELISA plates (Corning) were coated with 50 µL of 4 µg/mL 
recombinant Ebola Glycoprotein (a gift from Dr. Erica O. Saphire, The Scripps Research 
Institute) or Ebola virus VLPs. The coated plates were incubated at 4°C O/N, after which 
they were decanted and blocked with 2% milk in PBS for 2 h at RT.  After blocking, 1:5 
serially diluted antibodies were applied to the plates for 1h, after which 1:5000 diluted 
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donkey anti-human IgG HRP-conjuated secondary antibodies were applied (Jackson 
ImmunoResearch) for 1 h.  For detection, 50 µL TMB-Ultra substrate was applied for 15 
min before quenching with 50 µL 2 M H2SO4. Absorbance was measured at 450 nm 
using a Tecan M200 plate reader. Data were analyzed and fitted for EC50 using a 4-
parameter logistic nonlinear regression model in the Prism software. 
Surface Plasmon Resonance 
Antibody affinity to recombinant Ebola GP protein was measured by surface 
plasmon resonance using a BIAcore 3000 biosenor (Biacore). In order to fit the responses 
to 1:1 Langmuir binding model for more accurate affinity determination, antibodies were 
immobilized on the CM5 sensor chip (GE Healthcare) using the amine coupling 
chemistry. All binding experiments were done in HBS-EP buffer (10 mM HEPES pH 7.4, 
150 mM NaCl, 3.4 mM EDTA, and 0.005% P20 surfactant) (GE Healthcare). GP was 
injected in triplicates at concentrations 80, 100, 200, 300, 400, 500, and 600 nM with a 
flow rate of 60 μL/min for 2 min and a dissociation time of 10 min. Regeneration of the 
antibody was performed by a single injection of 100 mM citric acid, pH 3.0. The 
response generated by flowing GP over a bovine serum albumin (BSA) coupled surface 
was used as control and was consequently subtracted. All kinetic parameters were 
determined in BIAevaluation 3.0 software and were reported as the average of three 
technical replicates. 
Wild type virus ELISA assays 
All work with wild type virus was performed at BSL4 at Texas Biomedical 
Research Institute. All virus stocks were cultivated on Vero-E6 cells in DMEM with 2% 
FBS and antibiotics. When 80% of cells began showing a cytopathic effect, the culture 
supernatant containing virus was collected. Virus was purified as for VLPs by pelleting 
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cell debris and then pelleting virus from the culture supernatants through 20% sucrose in 
20 mM NaCl and 20 mM HEPES, pH 7.4. The virus pellets were resuspended in PBS and 
stored in aliquots at -80°C until needed. Virus titers were determined by conventional 
plaque assay using Vero-E6 cells. For ELISA assays, an aliquot of virus was thawed and 
the equivalent of 106 PFU of virus was diluted 1:3 into RIPA buffer. This was then 
diluted 1:100 into 10 mM sodium phosphate buffer, pH 7.4. After coating O/N, plates 
were washed with PBS containing 0.1% Tween-20 and incubated with each antibody 
starting at 1:100 of a 1 mg/mL stock and then over serial 4-fold dilutions on the plates. 
The secondary antibody was anti-human IgG HRP conjugate from Pierce. TMB Ultra 
substrate (Life Technologies) was used to detect antibody binding on plates. All assays 
were performed at least in duplicate and repeated 3 times. ELISAs were analyzed and 
fitted for EC50 using a 4-parameter logistic nonlinear regression model in the Prism 
software. 
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Figure 2-1: Isolation of antibodies by mining the paired VH:VL repertoire of  draining 
popliteal lymph node (PLN) antibody-secreting B cells. 
(a) Footpad immunization leads to a marked increase in cellularity within the ipsilateral 
popliteal lymph node relative to the contralateral lymph node (red and black arrows 
respectively). (b) PLN CD138+ cells isolated by magnetic sorting are deposited into 125 
pL wells on PDMS slides that also contain poly(dT) beads.  Cells are lysed in situ and 
mRNA is captured on the poly(dT) beads. (c) The poly(dT) beads are emulsified and 
VH:VL amplicons are generated following reverse transcription and overlap extension 
PCR. (d) VH:VL amplicons are sequenced using Illumina 2x250 MiSeq and the highest 
frequency VH:VL pairs are identified via bioinformatics analysis. (e) Highest frequency 
VH (orange) and VL (green) genes are synthesized and cloned into IgH and IgL expression 
vectors containing human IgG1 (blue) and human kappa (yellow) constant regions, 
respectively. (f) Following co-transfection into Expi293 cells, recombinant IgG 






Figure 2-2: Footpad immunization with EBOV VLPs. 
BALB/c mice were immunized with 5 µg Ebola VLPs in 10 µL PBS pH 7.4 emulsified in 
a 1:1 ratio with TiterMax Gold adjuvant with boosts on days 21 and 35. (a) Tail-vein 
bleeds were performed 7 days post day 35 boost, and antibody titers against VLPs 
measured in Mouse 1 (blue) and Mouse 2 (green). (b) Size comparison of the dissected 
ipsilateral (red arrow) and contralateral (black arrow) LNs. Ipsilateral LN: ~5mm in 












Figure 2-3: Characteristics of the PLN VH:VL repertoire in CD138+ antibody secreting 
cells.  
(a) Polarization of VH:VL repertoire after immunization with EBOV VLPs. The frequency 
of each unique CDRH3:CDRL3 antibody clonotype is shown as a percentage of total 
sequencing read counts. CDRH3 sequencing reads having at least 96% identity at the 
nucleotide level were clustered and compiled, then analyzed for corresponding CDRL3 
per pair. Sequences identified in <2 reads were excluded to minimize sequencing error. 
Inset: frequency of the ten most frequently observed CDRH3:CDRL3 antibody 
clonotypes from each mouse. (b, c) VH:VL gene family usage of unique CDRH3:CDRL3 













































Figure 2-4: Functional characterization of IgG antibodies isolated via mining of the 
PLN CD138+ B cell repertoire.  
(a) Binding to EBOV VLPs for antibodies encoded by the seven most frequently 
observed CDRH3:CDRL3 clonotypes from the sequenced PLN CD138+ B cell repertoires 
of each mouse. (b) Binding to purified EBOV recombinant GP for select antibodies as 
determined by ELISA. Binding to BSA as a control is shown in correspondingly colored 









Figure 2-5: BIACore sensorgrams for selected antibodies binding to recombinant EBOV 
GP. 
(a) ZM1.1, (b) ZM1.2, (c) ZM1.3, (d) ZM1.6, (e) ZM2.1.  Antibodies were immobilized 
on CM5 sensor chips and varying concentrations of GP were injected using a flow rate of 
60 µL/min for 2 min. Experiments were performed in three technical replicates, and all 



























Figure 2-6: Functional characterization of IgG antibodies isolated via mining of RESTV 
immunized PLN CD138+ B cell repertoire.  
Binding to RESTV recombinant GP for select antibodies as determined by ELISA. 
Curves were fitted using 4-parameter logistic non-linear regression. Error bars represent 













Figure 2-7: Binding of cross-reactive antibodies isolated via mining of the PLN CD138+ 
B cell repertoire to wild type EBOV, BDBV and SUDV viruses.  
ELISA assays using antibodies ZM1.7, ZM2.5, ZM2.6, and KZ52 for the detection of (a) 
wild type Ebola virus; (b) wild type Bundibugyo virus; and (c) wild type Sudan virus. 
Assays were performed in two technical replicates. Lines represent measurements fitted 























Sequence Gene Usage 
1 1 (ZM1.1) ARSFAY QQSNEDPYTF IGHV1-IGHJ3:IGKV3-IGKJ2 
 2 (ZM1.2) TGDGYYGFAY FQGSHVPFT IGHV6-IGHD2-IGHJ3:IGKV1-IGKJ4 
 3 (ZM1.3) ARGIGY WQGTHFPFT IGHV3-IGHJ3:IGKV1-IGKJ4 
 4 (ZM1.4) ARSTTATLDC QQSDSWPTLT IGHV14-IGHD1-IGHJ2:IGKV5-IGKJ5 
 5 (ZM1.5) ATISTATFPY QQSDSWPTLT IGHV1-IGHD1-IGHJ3:IGKV5-IGKJ5 
 6 (ZM1.6) ARRAMITTEGVDFDY QQSRKVPWT IGHV3-IGHD2-IGHJ2:IGKV3-IGKJ1 
 7 (ZM1.7) AREGYRYDWYFDV QQRSSYPLT IGHV1-IGHD2-IGHJ1:IGKV4-IGKJ5 
2 1 (ZM2.1) TRSVSDY WQGTHFPHT IGHV1-IGHD2-IGHJ2:IGKV1-IGKJ5 
 2 (ZM2.2) ARRTYRYDRFDY QQWSSDPLT IGHV1-IGHD2-IGHJ2:IGKV4-IGKJ5 
 3 (ZM2.3) TRRSNFPYYFDF QQSIEDPFT IGHV1-IGHD2-IGHJ2:IGKV3-IGKJ4 
 4 (ZM2.4) ARSELGATGFAY QQGQSYPIFT IGHV5-IGHD3-IGHJ3:IGKV15-IGKJ4 
 5 (ZM2.5) ARQKYGNYVLYWYFDV QQWNSNPPT IGHV5-IGHD2-IGHJ1:IGKV4-IGKJ4 
 6 (ZM2.6) TGMVTSY LQHWNYPYT IGHV6-IGHD2-IGHJ3:IGKV6-IGKJ2 
 7 (ZM2.7) VREGLGSYFDY QQYYNYPRT IGHV10-IGHD5-IGHJ2:IGKV8-IGKJ1 
 
Table 2-1: List of characterized EBOV antibodies sequenced from PLN CD138+ cells.  



















Table 2-2: SPR Binding kinetics and equilibrium dissociation constants (KD) towards 
uncleaved EBOV GP.  
Experiments were performed in three technical replicates and data were fit to a 1:1 














Antibody ID kon (M-1s-1) koff (s-1) KD (nM) 
ZM1.1 (3.12 ± 0.55) x104 (1.16 ± 0.07) x10-3 37.7 ± 0.55 
ZM1.2 (1.17 ± 0.41) x104 (1.71 ± 0.12) x10-3 156 ± 47.4 
ZM1.3 (3.12 ± 0.53) x104 (2.39 ± 0.62) x10-4 7.71 ± 1.77 
ZM1.6 (3.95 ± 0.7) x103 (2.46 ± 0.12) x10-3 635 ± 93.8 
ZM2.1 (1.47 ± 0.23) x104 (2.97 ± 0.07) x10-4 20.5 ± 3.44 
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Chapter 3:  Discovery of high affinity anti-ricin antibodies by B cell 
receptor sequencing and by yeast display of combinatorial VH:VL 
libraries from immunized animals2 
Ricin is a toxin that could potentially be used as a bioweapon. We identified anti-
ricin A chain antibodies by sequencing the antibody repertoire from immunized mice and 
by selecting high affinity antibodies using yeast surface display. These methods led to the 
isolation of multiple antibodies with high (sub-nanomolar) affinity. Interestingly, the 
antibodies identified by the two independent approaches are from the same clonal 
lineages, indicating for the first time that yeast surface display can identify native 
antibodies. The new antibodies represent well-characterized reagents for biodefense 
diagnostics and therapeutics development. 
INTRODUCTION 
Ricin is a toxin derived from the castor bean Ricinus communis, and it is 
classified as a Category B Agent by the Centers for Disease Control and Prevention in 
part because of its high lethality (LD50 about 22 μg/kg body weight for human) and ease 
of production (Lord et al., 1994). Ricin is composed of an enzymatic A chain, which 
deactivates eukaryotic ribosomes by depurinating adenine 4324 in the 28S rRNA of the 
60S ribosomal subunit, and a lectin B chain, which binds carbohydrates on the cell 
surface (Audi et al., 2005; Lord et al., 1994). As a result, ricin is a potent biological 
weapon, and past cases of malicious exposure to ricin highlight the need for both an 
increase in the sensitivity of diagnostics and for treatment after poisoning (Knight, 1979; 
Mayor, 2003). Antibodies to both the A chain and B chain of ricin have been produced 
                                                
2This chapter is reproduced with minor modifications from its initial publication: 
Wang, B., Lee, C.H., Johnson, E.L., Kluwe, C.A., Cunningham, J.C., Tanno, H., Crooks, R.M., Georgiou, 
G., and Ellington, A.D. (2016). Discovery of high affinity anti-ricin antibodies by B cell receptor 
sequencing and by yeast display of combinatorial VH:VL libraries from immunized animals. MAbs 8, 
1035–1044. Wang, B. designed and performed the experiments, and analyzed the data. 
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using hybridoma-based technology (Maddaloni et al., 2004; Mantis et al., 2006; Neal et 
al., 2010; Prigent et al., 2011), and by phage display screening of immune libraries 
reconstituted from the bone marrow of immunized cynomolgus macaques (Pelat et al., 
2009), resulting in antibodies with affinities ranging from 40 pM to 5 nM. However, 
there are currently no U.S. Food and Drug Administration-approved treatments for ricin 
poisoning, and the diagnostic potential of these reported antibodies has yet to be tested. 
In vitro screening of large combinatorial libraries using display technologies that 
rely on phage, bacteria, yeast, mammalian cells or even in vitro transcription/translation 
systems are widely employed for antibody discovery (Bradbury et al., 2011; Georgiou et 
al., 2014a; Hoogenboom, 2005). Combinatorial antibody libraries are constructed either 
by mining the natural diversity of immunoglobulin genes in immunized or antigen-naïve 
animals (Feldhaus et al., 2003; Hayhurst et al., 2003; Sheets et al., 1998), or by 
diversifying the complementarity-determining regions (CDRs) within one or more 
“scaffold” antibodies (Knappik et al., 2000). Variable heavy (VH) and variable light (VL) 
chain genes are then joined combinatorially, yielding, at least in theory, libraries that 
contain combinations of heavy chains joined with all possible light chains (Feldhaus et 
al., 2003; Hayhurst et al., 2003; Knappik et al., 2000; Sheets et al., 1998). Typically, 
immune libraries constructed from mRNA obtained from the spleen, bone marrow or 
from peripheral blood mononuclear cells (PBMCs, primarily in the case of human 
donors) are more likely to encode a significant fraction of antigen-specific antibodies and 
thus represent the most reliable route to high affinity antibodies (provided that the antigen 
is immunogenic) (Hayhurst et al., 2003; Maruyama et al., 1999). Isolation of high affinity 
antibodies from immune and other libraries is most readily accomplished by taking 
advantage of the quantitative nature of fluorescence-activated cell sorting (FACS)-based 
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library screening methods, and yeast display has been established as the dominant 
technology for screening libraries by FACS (Angelini et al., 2015). 
The power of combinatorial library screening has been validated by the 
identification and development of therapeutic antibodies that are now entering clinical 
trials (Brekke and Sandlie, 2003). However, certain antibodies isolated from 
combinatorial libraries may express at low yields in mammalian cells and display poor 
biophysical properties in vitro (Liu et al., 2014; Ponsel et al., 2011; Wang et al., 2014; 
Wörn and Plückthun, 2001; Xu et al., 2013), which can hamper their development into 
therapeutics. The random pairing of heavy and light chains in combinatorial libraries 
results in antibodies with non-natively paired VH and VL genes, and this is potentially one 
cause of poor antibody expression and stability (Tiller et al., 2013). Moreover, a recent 
report has suggested that several mouse and human VH germ-line genes exhibit strong 
preferential pairing with specific VL chains (Jayaram et al., 2012), and the random pairing 
of non-preferential VH and VL chains could lead to conformational incompatibilities, 
again affecting expression and stability. Enormous efforts have been made to advance 
screening techniques to remove antibodies with mediocre biophysical properties and on 
investigating methods to improve them in the past decade (Liu et al., 2014; Mcconnell et 
al., 2014; Rouet et al., 2014; Wang et al., 2014; Xu et al., 2013). 
Our lab has pioneered methods for the discovery of high affinity antigen-specific 
antibodies directly via mining of the immunoglobulin repertoire by capitalizing on next-
generation sequencing technologies without the need for screening (DeKosky et al., 2013, 
2015; Reddy et al., 2010; Wang et al., 2015a). Specifically, we developed methods for 
high-throughput determination of the natively paired VH:VL repertoire from single B cells 
(DeKosky et al., 2013, 2015). More recently, we have shown that antibody secreting B 
cells (CD138+ plasmablasts) within the draining lymph node are overwhelmingly antigen-
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specific, and that antibodies derived from these cells exhibit high binding affinity (Wang 
et al., 2015a). 
In this report, we sought to compare the isolation of high-affinity anti-ricin 
antibodies via mining of the draining lymph node repertoire and via yeast display of 
immune combinatorial libraries constructed from antibody mRNAs obtained from spleen 
or bone marrow cells. Overall, both approaches yielded strong ricin A chain binders (the 
lowest Kd values were 0.97 and 0.58 nM, respectively, for these two methods). 
Interestingly, we found that antibodies isolated by yeast display from combinatorial 
libraries in which the VH and VL from spleen or bone marrow had been randomly paired 
were clonal relatives of antibodies identified via mining of the draining lymph node 
repertoire, and comprised authentic, natively paired, VH and VL sequences. Thus, in 
hyperimmune animals where antigen-specific antibodies comprise a significant portion of 
the repertoire (Becker et al., 2010; Kuroiwa et al., 2009; Kurosawa et al., 2012; Reddy et 
al., 2010; Wang et al., 2015a), flow cytometric screening of libraries constructed via the 
random pairing of VH and VL genes can nonetheless result in the isolation of native 
antibodies. 
RESULTS 
Overview of the experimental approach 
As we have previously shown, mouse footpad immunization results in a strong 
immune response in the popliteal draining lymph node (DLN), characterized by the 
robust expansion of antibody secreting B cells (CD138+ plasmablasts) (Wang et al., 
2015a). Analysis of the DLN CD138+ B cell antibody repertoire overwhelmingly 
revealed that the most highly represented sequences, i.e., those present in the largest 
number of reads, are antigen-specific (Wang et al., 2015a). Therefore, we sought to 
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explore the antibody repertoire in DLN antibody-secreting B cells, and to compare 
antigen-specific antibodies with those selected from bone marrow and spleen 
combinatorial libraries, which are commonly used in antibody discovery efforts 
following intraperitoneal or subcutaneous immunization (Hayhurst et al., 2003; Pelat et 
al., 2009; Saggy et al., 2012). In contrast, samples from the DLN could only support 
high-throughput VH:VL sequencing and repertoire analysis, as we were limited by the 
number of cells. Four mice were immunized by footpad injection with ricin A chain in 
TiterMax Gold adjuvant (Fig. 3-1A), followed by two booster immunizations after 14 and 
28 days, after which all four mice generated significant titers (>1:10,000) against ricin A 
chain (Fig. 3-2A). One more booster immunization was performed, after which even 
higher titers were reached (Fig. 3-2B). Mice were sacrificed six days after the final 
booster immunization, at which point the draining lymph node was observed to be 
enlarged compared to the contralateral lymph node. Spleen and bone marrow were 
collected to screen for antigen-specific antibodies (Fig. 3-1B), and the draining lymph 
node was collected as well for VH:VL mining (Fig. 3-1C). 
Isolation of high affinity ricin A chain antibodies by yeast display of combinatorial 
libraries 
Single-chain variable fragment (scFv) libraries were constructed using mRNA 
from ~ 5 x 106 total splenocytes, and separately from femur bone marrow cells (Fig. 3-
1B). Briefly, VH and VL genes were amplified separately, paired combinatorially by 
overlap extension-polymerase chain reaction that also introduced a (Gly4Ser)3 linker 
(Hayhurst et al., 2003), and then subcloned into the yeast display vector pCTCON2 via 
homologous recombination (Chao et al., 2006). 
Two libraries of ~ 2 x 106 transformants each (bone marrow-derived and 
splenocyte-derived) were obtained. Screening was performed by carrying out one round 
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of magnetic-activated cell sorting (MACS), and then three rounds of FACS with 
progressively more stringent gates that collected cells positive both for expression (using 
Alexa Fluor 488-labeled anti-c-Myc) and for ricin A chain binding (using Alexa Fluor 
633-labeled ricin A chain) (Fig. 3-3). For the first two rounds of selection, ricin A chain 
was used at a 1 μM concentration. Prior to selection, both libraries showed little binding 
to ricin A chain (Fig. 3-3A and B, before selection). Significant enrichment of cells that 
stained positively both with fluorescent anti-c-Myc antibody and ricin A chain was 
observed from both libraries after the second round (Fig. 3-3A and B, after 1st FACS). 
Subsequently, ricin A chain concentrations of 200 nM and 40 nM were used for the third 
and fourth rounds of sorting, respectively. After the fourth round, almost all of the cells 
that expressed scFv also showed binding to ricin A chain (Fig. 3-3A and B, after 3rd 
FACS). 
Twenty colonies from each library were sequenced, yielding a total of 5 unique 
clones (3 from the bone marrow-derived library and 2 from the splenocyte-derived 
library), indicating that screening had led to convergence of the libraries to a small 
number of scFv sequences (Table 3-1). Apparent equilibrium binding constants (Kd) for 
these 5 clones were estimated by incubating yeast cells displaying the respective 
antibodies with different concentrations of ricin A chain, ranging from 0.09 to 600 nM, 
and then measuring the mean fluorescence intensity of binding at each concentration by 
FACS.  Binding constants were calculated using a Langmuir 1:1 binding model (Chao et 
al., 2006). All 5 antibodies demonstrated low nanomolar affinities binding to ricin A 
chain (Table 3-2). These 5 antibodies were then expressed in E. coli as single-chain 
antibodies (scAbs, scFv fused with human kappa light chain at the C-terminus (Hayhurst 
et al., 2003)), and purified to >95% homogeneity by Ni-NTA chromatography (as 
determined by SDS-PAGE). The antibodies were further purified by size-exclusion 
 61 
chromatography, which also revealed that all antibodies were monomeric. Surface 
plasmon resonance (SPR) analyses indicated that, consistent with the flow cytometric 
analyses (Chao et al., 2006), all 5 antibodies displayed high affinity binding to ricin A 
chain (Table 3-2, Fig. 3-4). 
The question of whether in vitro screening technologies can identify native 
antibodies in a repertoire has generally not been addressed; the two methods often return 
different antigen-specific antibodies. Different screening platforms lead to the 
identification of different antibodies, but some platforms seem to return antibodies that 
are of low abundance or apparently not present at all (Bowley et al., 2007; Saggy et al., 
2012). The identification of antibodies via yeast display presented an opportunity to 
compare the results with the natural repertoire, and thus we sequenced both the bone 
marrow and spleen VH and VL repertoires using an Illumina 2 x 250 Miseq platform. 
From the same 5 x 106 cells of bone marrow and spleen from a given mouse that were 
used for yeast library construction, about 106 and 7 x 105 reads, respectively, were 
obtained for VH repertoires, from which 8735 and 7057 unique clonotypes (defined as the 
group of VH sequences that share the same germ-line V and J segments, and have >90% 
amino acid identity in their CDRH3s (Lavinder et al., 2014) were identified (Table 3-3). 
Similar to previous reports (Lu et al., 2014; Reddy et al., 2010), both repertoires were 
observed to have skewed germ-line V gene usage. For example, both repertoires showed 
biases for IGHV1, 5, 14, and IGKV1, 4, 6 families (Fig. 3-5A, B), with IGKV4 as the 
most commonly used light chain family in the bone marrow, and IGKV6 as the most 
commonly used light chain in the spleen. We noticed the preferential usage of the IGKV1 
family in bone marrow relative to spleen, and of the IGKV6 family in spleen relative to 
bone marrow. It will be interesting to determine if similar repertoire biases towards 
specific germline light chain families are observed with other antigens and adjuvant 
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combinations. Both repertoires showed a CDRH3 length distribution comparable to those 
previously reported from animals immunized with different antigens (Reddy et al., 2010), 
with a median CDRH3 length of 13 amino acids in the bone marrow repertoire and 11 
amino acids in the spleen repertoire (Fig. 3-5C). 
Importantly, we now find that the antibodies identified by yeast surface display 
are amongst the most abundant antibodies in the sequenced repertoire (Table 3-1). This 
indicates for the first time that yeast surface display of combinatorial libraries can 
identify native antibodies in the repertoire. 
Isolation of high affinity anti-ricin A chain antibodies by next-generation sequencing 
of DLN B cells 
CD138+ antibody secreting B cells were isolated from the draining lymph node 
and the paired VH:VL repertoire was determined, as previously described (Wang et al., 
2015a). Briefly, a total of 90,000 CD138+ antibody secreting cells were isolated by 
magnetic sorting by first depleting CD45R+, CD49b+, and CD19+ cells, and then 
enriching for CD138+ cells. Approximately 40,000 antibody secreting cells were 
deposited into microfabricated nanowell plates such that >98% of wells contained a 
single cell, after which poly(dT) magnetic beads were added to capture mRNAs, the cells 
were lysed, and the poly(dT) beads were collected. The beads were emulsified, and 
overlap extension RT-PCR was performed to synthesize linked VH:VL amplicons (Fig. 3-
1C) (DeKosky et al., 2013). The region of the linked amplicons comprising CDRH3 and 
CDRL3 was then sequenced in an Illumina MiSeq 2 x 250 run. Full-length VH and VL 
sequences were identified in separate MiSeq 2 x 250 runs. After bioinformatics analysis 
(DeKosky et al., 2013), 212 unique VH:VL pairs were identified in the draining lymph 
node repertoire, and these showed great polarization, indicative of clonal expansion. 
Specifically, the top 10 most abundant VH:VL pairs constituted 65.8% of the total reads 
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(Fig. 3-6A). The virtual absence of antibodies using IGLV families in the repertoire was 
expected, as only 5% of all mouse antibodies use the lambda light chain (Lu et al., 2014). 
Comparisons with mouse antibody repertoires generated by immunization with 
other antigens showed similar germ-line gene usage between the anti-ricin A chain 
antibody repertoire and other repertoires (Fig. 3-6B) (Reddy et al., 2010; Wang et al., 
2015a). The CDRH3 length distribution in CD138+ antibody secreting cells from the 
draining lymph node showed three peaks at 12, 13, and 15 amino acids (Fig. 3-6C). 
Synthetic genes for the top 10 highest frequency paired VH:VL sequences from the 
DLN repertoire were constructed and the respective mouse-human chimeric antibodies 
(mouse VH fused with the human IgG1 constant domain, and mouse VL fused with the 
human kappa constant domain) were expressed in Expi293 cells and purified. 4/10 
recombinant antibodies displayed binding by ELISA (Table 3-4, Fig. 3-7). SPR analysis 
was used to obtain antigen-binding kinetics for these 4 clones (Table 3-5, Fig. 3-4). All 
but one antibody showed high affinity binding to the ricin A chain. Interestingly, the 
affinities of the antibodies that bound ricin A chain correlated with their abundance in the 
VH:VL repertoire, with the antibody displaying the lowest Kd (RAM1.2) being the most 
abundant. 
We compared the native antibodies recovered from the DLN to yeast display-
selected antibodies from the bone marrow and spleen combinatorial libraries. 
Interestingly, BM1, BM3, BM17 and SP19 were found to share germ-line V and J 
segments with RAM1.5, and SP1 had the same germ-line V and J segments as RAM1.4. 
The two groups of antibodies also had the same VH:VL pairing. Furthermore, antibodies 
recovered from the DLN without selection had very similar CDRH3s with those isolated 
by yeast display from bone marrow and spleen (Table 3-1, 3-4), as well as additional 
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amino acid substitutions, indicating that they correspond to somatic variants derived from 
the same antibody lineage during clonal expansion (Fig. 3-8). 
DISCUSSION 
In vitro screening of antibody libraries constructed from different sources 
(synthetic, naïve, or immune) is one of the most commonly used techniques for antibody 
discovery (Bradbury et al., 2011; Hoogenboom, 2005). In this work, we identified anti-
ricin A chain antibodies by eliciting an immune response in mice and then exploring the 
resultant antibody repertoires via both yeast display of combinatorial libraries from the 
bone marrow and spleen and paired VH:VL sequencing from the draining lymph node. 
While both approaches generated high affinity clones (Kd ranging from 0.55 nM 
to 6.12 nM), as has previously been observed (Bowley et al., 2007), unexpectedly the 
antibodies generated by these two very different approaches were found to be clonal 
relatives. Different amino acids encoded by different nucleotides in the isolated 
antibodies from different lymphoid organs indicated that BM1, BM3, BM17 (derived 
from bone marrow using yeast display), SP19 (derived from the spleen using yeast 
display) and RAM1.5 (derived from the draining lymph node using paired VH:VL 
sequencing), and separately SP1 and RAM1.4 were clonal variants (Fig. 3-8). A previous 
report has shown that while naïve mouse spleen and lymph node repertoires share some 
common CDRH3s, the scFvs isolated from these lymphoid organs following 
intraperitoneal and subcutaneous immunization were unique (Venet et al., 2013). In 
contrast, when we probed different lymphoid organs, clonal variants were obtained. 
These differing conclusions may reflect differences in the immunization routes used, the 
numbers of boost immunizations, and significant differences introduced by the 
expression biases in phage compared to yeast display. The clonal variants we isolated 
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from different lymphoid organs indicate that these antibodies were likely encoded by the 
same ancestral B cells that homed to different lymphoid organs and experienced clonal 
expansion there. 
We have previously shown that by dissecting the draining lymph node antibody 
repertoire with paired VH:VL sequencing, the highly abundant clones were usually antigen 
specific as a result of clonal expansion (Wang et al., 2015a). Here, we again showed that 
the highly abundant clones in the draining lymph node probed with paired VH:VL 
sequencing encoded high-affinity, antigen-specific antibodies. Comparison of the 
antibodies isolated using these two approaches supports our hypothesis that yeast display 
can recover native antibodies in a repertoire, as antibodies isolated by yeast display are 
clonal variants of those isolated by paired VH:VL sequencing, which identifies native 
VH:VL pairings. Given the relative abundance of the VH and VL sequences of antibodies in 
the bone marrow and spleen repertoires, the calculated probability of obtaining these 
native antibodies by combinatorially random pairing would be about 0.2%. Thus, in 
hyperimmunized animals the proportion of randomly paired VH and VL genes is 
sufficiently high that natively paired heavy and light chains occur. Moreover, high 
affinity native pairs can be isolated following yeast surface expression and FACS. To our 
knowledge this is the first report that yeast display selections can identify native 
antibodies from the immune repertoire. 
The fact that an in vitro combinatorial library screening method can identify 
native V gene pairs is relevant for antibody discovery. Numerous successes in developing 
antibody drugs from combinatorial libraries generally validate this approach (Brekke and 
Sandlie, 2003). However, some high-affinity antibodies identified by library screening 
have mediocre biophysical properties, such as low yield and poor stability (Liu et al., 
2014; Ponsel et al., 2011; Wang et al., 2014; Wörn and Plückthun, 2001; Xu et al., 2013). 
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Such deficiencies are thought to emanate from random or non-native pairings of VH and 
VL that lead to unfavorable conformations that in turn promote poor biophysical 
properties (Jayaram et al., 2012; Tiller et al., 2013). Another contributor may be that 
expression in a non-native host (i.e., mouse antibody libraries screened by phage display) 
leads to selection at the expression level against certain clones (Bowley et al., 2007). In 
contrast, antibodies with natively paired heavy and light chains, such as those isolated 
from hybridomas, express better, and in general show much better stability (Dessain et 
al., 2008; Jayaram et al., 2012; Tiller et al., 2013). Our methods can therefore potentially 
streamline the huge amount of effort put into the discovery process (Liu et al., 2014; 
Mcconnell et al., 2014; Rouet et al., 2014; Wörn and Plückthun, 2001; Xu et al., 2013). 
Our results support the utility of next-generation sequencing in combinatorial 
library screening (Georgiou et al., 2014a; Reddy et al., 2010; Wang et al., 2015a). 
Hyperimmunization leads to a high degree of polarization of the B-cell repertoire in a 
particular compartment, such that the dominant antibodies are highly represented and 
combinatorial screening by a technique with low expression bias, such as yeast display, 
can further yield high-affinity native antibodies. The high-affinity anti-ricin A chain 
antibodies we identified may provide a greater diversity of reagents for both diagnostics 
and therapeutics. 
MATERIALS AND METHODS 
Cell line and media 
The yeast strain EBY100 (MATa AGA1::GAL1-AGA1::URA3 ura3-52 trp1 
leu2Δ200 his3Δ200 pep4::HIS3 prb11.6R can1 GAL) was used for library construction 
and screening. Yeast cells were maintained in YPD medium (20 g/l dextrose, 20 g/l 
peptone, and 10 g/l yeast extract); after library transformation, they were maintained in 
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SDCAA medium (20 g/l dextrose, 6.7 g/l yeast nitrogen base, 5 g/l casamino acids, 8.56 
g/l NaH2PO4.H2O, and 10.2 g/l Na2HPO4.7H2O). SGCAA medium (identical to SDCAA 
except 20 g/l galactose is used instead of dextrose) was used for library induction. E. coli 
strain DH10β was used for subcloning, and E.coli strain Jude-1 was used for soluble 
scAb expression. Expi293 cells (Invitrogen) were used for IgG expression, and were 
maintained in Expi293 expression medium (Invitrogen). 
Antigen and antibodies  
Ricin A chain was purchased from Sigma-Aldrich (cat# L9514). It was 
biotinylated using an EZ-Link Sulfo-NHS-LC-Biotin kit (Thermo Scientific). Chicken 
anti-c-Myc IgY, Alexa Fluor 488-goat anti-chicken IgG (GaC-488), and streptavidin-
Alexa Fluor 633 (SA-633) were obtained from Invitrogen (cat# A-21281, A-11039, and 
S21375, respectively). Anti-biotin microbeads were purchased from Miltenyi Biotec 
(cat# 130-090-485). 
Mouse immunizations 
This study was approved by the University of Texas Institutional Animal Care 
and Use Committee under protocol# AUP-2013-00009. Ricin A chain was mixed with 
TiterMax Gold adjuvant (Sigma-Aldrich, cat# T2684) at a 1:1 ratio and pipetted several 
times to obtain stable emulsions for immunization. On day 1, 4 female BALB/c mice at 6 
weeks of age (Jackson Laboratory) were injected subcutaneously at the left hind footpad 
with 5 μg of ricin A chain in 25 μl antigen adjuvant mixture. A booster immunization 
was performed on day 14. 7 days after the booster immunization, the serum antibody 
titers against ricin A chain were determined. About 30 μl of blood was collected from 
each mouse at a small tail vein incision made with a scalpel blade, and coagulated at 
room temperature (RT) for 30 min. Following centrifugation at 13000 rpm for 15 min, 
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the supernatant (serum) was used for ELISAs. The serum was first serially diluted with 
phosphate-buffered saline (PBS) +2% milk (PBSB) at a 1:3 ratio from 1:100 to 
1:218,700. The diluted serum was applied in triplicate onto ELISA plates (Corning) that 
had been coated with 50 μl of 4 μg/ml of ricin A chain overnight (O/N) at 4oC and then 
blocked with PBSB at RT for 2 hours. After incubation at RT for 1 hour, plates were 
washed with PBS+0.05% Tween-20 (PBST), followed by adding 50 μl of a 1:5000 
diluted horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody (Jackson 
ImmunoResearch, cat# 115-035-166). After 1 hr incubation, plates were washed again 
with PBST, after which 50 μl of TMB Ultra ELISA substrate (Thermo Scientific, cat# 
34028) was added. The reaction was quenched after 10 min with 50 μl of 2 M H2SO4. 
Absorbance at 450 nm was determined using a Tecan M200 plate reader, and the serum 
titer was calculated as the dilution at which the absorbance was 3 times higher than 
background. The second booster was performed on day 28, after which significant titers 
(>1:10,000) were generated in all mice. The final booster was performed on day 42, and 6 
d later, mice were sacrificed for lymphoid organ collection. 
Lymphoid organ collection 
Bone marrow, spleen, and draining lymph node tissues were collected separately. 
30 min before sacrifice, 10 μl 2% Evans Blue in PBS (Sigma-Aldirch, w/v, cat# E2129) 
was injected into the left hind footpad. After CO2 asphyxiation and cervical dislocation, 
the blue-stained popliteal lymph node behind the knee was collected. The spleen was also 
collected. For bone marrow collection, after clipping the ends of the tibias and femurs, 
bone marrow was flushed out with PBS+0.1% bovine serum albumin (BSA)+2 mM 
EDTA (PBSM) using a syringe. Each lymphoid organ tissue sample was first 
mechanically disrupted using a needle, then passed through a 70 μm cell strainer 
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(Corning) to collect single cells. The single cell suspension of each lymphoid organ was 
washed with 20 ml of PBSM buffer and resuspended in 2 ml red blood cell lysis buffer 
(155 mM NH4Cl, 12 mM NaHCO3, and 0.1 mM EDTA). After incubation at RT for 5 
min, cells were diluted with 20 ml of PBS and then spun down. Cells were washed twice 
more with PBSM buffer, then cells from the bone marrow and spleen were used for yeast 
library construction, and cells from draining lymph node were used for high-throughput 
VH:VL pairing. 
Yeast library construction for bone marrow and spleen repertoires 
Cells from the bone marrow and spleen were resuspended in TRI Reagent 
(Invitrogen), and RNA was extracted from each sample. cDNA was generated using 200 
ng of RNA as a template with the SuperScript III First-Strand synthesis kit (Invitrogen). 
VH and VL sequences were amplified using mouse V gene specific primers. For scFv 
library construction, 50 ng of VH and VL DNA were used as templates for overlap 
extension PCR, and amplified with primers that contained 50 nucleotides at each end that 
were in common with the display vector, which should be sufficient to promote 
homologous recombination upon yeast transformation. The display vector pCTCON2 
was linearized by NheI and BamHI digestion (Chao et al., 2006) and the digested 
backbone was purified and co-transformed with 5-fold mass excess of scFv fragments 
into electrocompetent yeast cells (Benatuil et al., 2010). The libraries were cultured in 
SDCAA medium at 30oC for 2 d. 
Yeast library screening 
Cells were induced in SGCAA medium at 20oC for 2 d. For the 1st round of 
selection, 2 x 107 cells (10-fold coverage relative to the number of transformants) were 
incubated with 1 μM biotinylated ricin A chain at RT for 1 hr and washed thoroughly 
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with PBS+0.5% BSA+2 mM EDTA (PBSA) to remove any unbound ricin A chain 
protein. Cells were then mixed with 400 μl of anti-biotin microbeads and incubated at 
4oC for 30 min, and washed again. Cells that bound ricin A chain were selected using 
MidiMACS system (Miltenyi Biotec), and recovered in SDCAA medium at 30oC. For the 
2nd round of selection, 107 cells in 200 μl PBS+0.1% BSA (PBSF) were labeled with 1 
μM biotinylated ricin A chain and 4 μg/ml chicken anti-c-Myc IgY at RT for 1hr. After 
washing with PBSF, cells were incubated with 5 μg/ml SA-633 and 5 μg/ml GaC-488 at 
4oC for 30 min. After washing, cells were resuspended in PBSF buffer and sorted using 
FACS Aria (BD Bioscience). Gated cells were collected from the double positive 
quadrant as shown in Fig. 3-3. The subsequent 2 rounds of selection were performed in a 
similar way, except that the concentration of ricin A chain used was decreased to 200 nM 
and 40 nM, respectively. After 4 rounds of selection, 20 random colonies from each 
library were picked, and plasmids were isolated using Zymoprep Yeast Plasmid Miniprep 
II kit (Zymo Research). Plasmids were amplified in E. coli DH10β and sequenced. Three 
and two unique clones were thus isolated from the bone marrow and spleen libraries, 
respectively. 
Plasmids encoding the 5 unique antibody clones above were re-transformed into 
strain EBY100. Cells were cultured and induced for scFv expression as described above. 
106 cells were labeled with 1:3 serially diluted ricin A chain, ranging from 0.09 nM to 
600 nM. The labeling process was the same as that used for library sorting. After 
labeling, cells were analyzed on BD FACS Aria and the mean fluorescence intensity 
(MFI) values were used to calculate apparent equilibrium binding constant (Kd), as 
described (Chao et al., 2006). 
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scAb expression and characterization 
For soluble antibody purification, antibody genes were subcloned into pMopac16 
vector and expressed as scAb fragments in E.coli Jude-1 cells (Hayhurst et al., 2003) and 
then purified by Ni-NTA chromatography according to the manufacturer’s instructions 
(Thermo Scientific). After elution, proteins were dialyzed in PBS, then loaded onto a 
Hiload 16/600 Superdex 75 pg column (GE Healthcare) and antibody-containing 
fractions were pooled and concentrated to 2 mg/ml. 
For affinity validation, SPR was performed for each antibody clone using a 
BIAcore 3000 biosenor (Biacore). About 400 RU (response units) of scAbs were 
immobilized on the CM5 sensor chip (GE Healthcare) using amine coupling chemistry. 
All binding experiments were done in HBS-EP buffer (10 mM HEPES pH 7.4, 150 mM 
NaCl, 3.4 mM EDTA, and 0.005% P20 surfactant) (GE Healthcare). Ricin A chain was 
injected at concentrations of 25, 50, 100, 200, and 400 nM with a flow rate of 30 μL/min 
for 2 min and a dissociation time of 10 min. The chip was regenerated after each injection 
by 100 mM citric acid, pH 3.0. The response generated by flowing ricin A chain over a 
BSA-coupled surface was used as control and consequently subtracted. Experiments were 
carried out in triplicates. All kinetic parameters were determined in BIAevaluation 3.0 
software using a 1:1 Langmuir model and were reported as the average of the three 
technical replicates. 
V gene repertoire sequencing and analysis 
VH and VL cDNA for bone marrow and spleen samples (the same cDNAs used for 
yeast library construction) were prepared and sequenced using the Illumina 2 x 250 
paired end Miseq platform as described previously (DeKosky et al., 2013). Briefly, raw 
sequences were first filtered for sequences containing at least half of the nucleotides at a 
minimum Phred quality score of 20 to obtain high quality sequences, then assembled to 
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obtain full length VH and VL sequences, respectively. Sequences represented by at least 2 
reads were submitted to IMGT (the international immunogenetics information system, 
www.imgt.org) High V-Quest analysis (Lefranc et al., 2009) and those with productive 
VH or VL, and in-frame V(D)J junctions (CDRH3 or CDRL3) were analyzed further. 
Paired VH:VL sequencing of antibody secreting cells from the draining lymph node 
From single cell suspension of the draining lymph node, CD138+ antibody 
secreting B cells were isolated using a mouse CD138+ Plasma Cell Isolation kit (Miltenyi 
Biotec) (Wang et al., 2015a). The paired VH:VL gene repertoire was determined as 
described (DeKosky et al., 2013). Briefly, isolated single cells were deposited into 125 
pL wells in PDMS slides together with poly(dT) magnetic beads (Invitrogen). After cell 
lysis in situ, beads with captured mRNA from the same cell were collected, washed, and 
emulsified. Mouse V gene specific primers were used to link endogenous VH and VL in 
the subsequent emulsion overlap extension RT-PCR. A second nested PCR was used to 
amplify the linked VH:VL pairs. Sequencing was performed by Illumina 2 x 250 paired 
end Miseq. The raw Miseq reads were filtered for reads where at least half of the 
nucleotides had a minimum Phred quality score of 20 to remove low-quality reads, and 
were then submitted to IMGT for V(D)J germ-line alignment (Lefranc et al., 2009). 
Sequence data were again filtered for productive VH or VL, and for in-frame V(D)J 
junctions (CDRH3 or CDRL3), and were then matched using their Illumina read IDs. 
CDRH3 nucleotide sequences were clustered to 96% identity, and CDRH3:CDRL3 pairs 
represented by 2 or more reads were rank-ordered. In two separate sequencing runs the 
complete VH and VL sequences encoded within the linked VH:VL amplicons were 
determined. The sequences for the VH:VL junction and the separate VH and VL sequences 
 73 
were assembled to yield natively paired full length VH and VL sequences, as described 
(DeKosky et al., 2013). 
Antibody expression and characterization 
Consensus VH and VL sequences of the top 10 most abundant antibodies from the 
draining lymph node were synthesized using gblocks (IDT) and subcloned into 
pcDNA3.4 vectors (Invitrogen) as fusions with human IgG1 and kappa constant domains, 
respectively. After sequence verification, the heavy and light chain plasmids were mixed 
at 1:3 ratio, and transfected into Expi293 cells for antibody expression. Six days after 
transfection, the supernatant was collected and antibodies were purified using protein A 
chromatography (Thermo Scientific). 
To verify the specificity of these antibodies, ELISAs were carried out with both 
ricin A chain and BSA as a control. ELISA plates were coated with 50 μl of 4 μg/ml ricin 
A chain or BSA at 4oC O/N. On the next day, plates were blocked with PBSB at RT for 2 
hr. After that, 1:5 serially diluted antibodies with concentrations ranging from 300 nM to 
3.84 pM were added to the plates and the plates were incubated at RT for 1 hr. After 
washing with PBST, 50 μl of 1:5000 diluted HRP-conjugated donkey anti-human 
antibody (Jackson ImmunoResearch, cat# 709-035-149) was added and the plates were 
again incubated at RT for 1hr. After washing with PBST, 50 μl of TMB substrate was 
added and the reaction was stopped after 10 min by adding 50 μl of 2 M H2SO4. The 
absorbance at 450 nm was read and EC50 was calculated. For each antibody that showed 
binding to ricin A chain, affinity determinations were carried out via SPR analyses, as 
described above for scAbs. 
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Figure 3-1: Overview of the experimental approach.  
(A) Mouse is immunized at footpad with ricin A chain, and peripheral lymphoid organs, 
including bone marrow, spleen, and draining lymph node are isolated after three booster 
immunizations. (B) Total cells in bone marrow and spleen are collected, and VH and VL 
mRNA are reverse transcribed and amplified, which are used to construct scFv libraries, 
respectively. These are selected against ricin A chain using yeast surface display to 
isolate high-affinity binders. VH and VL cDNAs are also sequenced on an Illumina 
platfrom. (C) CD138+ antibody secreting cells are isolated from draining lymph node, and 































Figure 3-2: Serum titers of mice immunized with ricin A chain.  
Titers after the 2nd booster immunization (A) and after the 3rd booster immunization (B) 
are shown. (mouse 1 (used for antibody discovery): red circle; mouse 2: green star; 

















Figure 3-3: Selection of libraries constructed from bone marrow and spleen antibody 
repertoires.  
Cells are doubly stained with chicken anti-c-Myc IgY/GaC-488 for scFv surface 
expression and biotinylated ricin A chain/SA-633 for antigen binding. (A) Bivariate plots 
are shown for bone marrow antibody library stained with 100 nM ricin A chain before 
selection, after MACS, after 1st FACS, after 2nd FACS, and after 3rd FACS, with x axis 
being surface expression, and y axis being antigen binding. (B) Bivariate plots are shown 
for spleen antibody library stained with 100 nM ricin A chain before and after each round 
of selection. For both libraries, cells in the upper-right quadrant (both express scFv on the 
surface and bind ricin A chain) are sought. Cells falling within strict FACS sort gates 
designed to ensure enrichment of clones showing increased binding to ricin A chain are 




































































































Figure 3-4: SPR sensorgrams for BM1(A), BM3(B), BM17(C), SP1(D), and SP19(E) 
scAbs and RAM1.2(F), RAM1.4(G), RAM1.5(H), and RAM1.10(I) IgGs.  











Figure 3-5: Characteristics of bone marrow and spleen antibody repertoires from the 
same mouse immunized with ricin A chain.  
(A) Germ-line VH gene usage in bone marrow and spleen repertoires. (B) Germ-line VL 
gene usage in the two repertoires. (C) CDRH3 length distribution in the two repertoires. 

















Figure 3-6: Characteristics of CD138+ antibody-secreting cells repertoire in draining 
lymph node from mouse immunized with ricin A chain.  
(A) The frequency of each unique antibody clone in the repertoire, which is calculated as 
the percentage of its read counts in the read counts of all clones, is shown with its rank, 
which is ordered by the number of read counts of each unique clone. Clones with only 1 
read are removed, and CDRH3 nucleotide sequences are clustered to 96% identity. Inset 
shows the distribution of the top 10 most abundant clones in the repertoire. (B) Germ-line 
V gene family usage in the same repertoire is shown. (C) CDRH3 length (calculated as 
amino acid length) distribution of antibodies in the repertoire is shown as the percentage 






























Figure 3-7: Characterization of the 4 antibodies isolated from CD138+ antibody 
secreting cells in the draining lymph node.  
Reactivity of the antibodies to ricin A chain is determined by ELISA. EC50 for the 4 













Figure 3-8: Sequence comparison between yeast surface display and next-generation 
sequencing discovered antibodies.  
(A), (B) VH alignments of BM1, BM3, BM17, SP19 and RAM1.5 and of SP1 and 
RAM1.4 showed mutations through the complete VH sequences, indicating they are 
somatic variants. (C), (D) VL alignments of BM1/BM3/BM17, SP19 and RAM1.5 and of 

















Table 3-1: List of the antibodies isolated from the bone marrow and spleen 
combinatorial libraries by yeast display and abundance of their VH and VL 
sequences in the corresponding repertoires assessed by next-generation 
sequencing.  
Note that BM3 and BM17 have the same CDRH3 sequences, but differ in sequence 












Antibody Source CDRH3: CDRL3 Gene usage VH:VL 
abundance (percentage and rank) 
 













































Table 3-2: The binding kinetics of the antibodies isolated from bone marrow and spleen 

















Antibody  Kd 
(nM, determined by yeast display titration) 
Binding kinetics determined by SPR 
kon (M-1s-1) koff (s-1) Kd (nM) 
BM1  10.3 (2.09±0.04)x 105 (9.7±0.52)x10-4 4.64±0.33 
BM3  2.76 (1.13±0.03)x105 (3.41±0.23)x10-4 3.03±0.12 
BM17  2.96 (2.5±0.13)x105 (1.36±0.006)x10-3 5.44±0.27 
SP1  4.25 (2.28±0.07)x105 (3.72±0.06)x10-4 1.64±0.08 




Tissue Region Total sequence reads unique productive gene unique clonotypes 
bone marrow VH 1078639 849735 8735  
 VL 542905 385398  
spleen VH 690554 370357 7057 
 VL 696061 410954  
 






















Table 3-4: List of the antibodies isolated from CD138+ antibody-secreting cells in the 















Antibody Rank in the repertoire CDRH3:CDRL3 Gene usage 
RAM1.2 2 CARPTLLYGSSPCFDYW: 
CQQWSSSPTF 
IGHV1-IGHJ2:IGKV4-IGKJ4 
RAM1.4 4 CTRERTWYGTFYAMDYW: 
CHQYHRSPYTF 
IGHV1-IGHD2-IGHJ4:IGKV4-IGKJ2 
RAM1.5 5 CTRSEYVDFGWFAYW: 
CQQYHSYPRTF 
IGHV1-IGHD2-IGHJ3:IGKV4-IGKJ1 





Antibody EC50  
(nM,determined 
by ELISA) 
SPR binding kinetics 
kon (M-1s-1) koff (s-1) Kd (nM) 
RAM1.2 0.186 (3.88±0.36)x105 (3.73±0.13)x10-4 0.97±0.11 
RAM1.4 0.284 (1.28±0.12)x105 (4.93±0.11)x10-4 3.89±0.35 
RAM1.5 3.21 (9.84±0.51)x104 (6.01±0.12)x10-4 6.12±0.19 
RAM1.10 20.9 (5.46±2.4)x104 0.149±0.01 (3.12±1.36)x103 
 
Table 3-5: The binding kinetics of the antibodies isolated from the draining lymph node 



















Chapter 4: High-throughput mining of native antibody repertoires  
In chapters 2 and 3, I have described the development and adaptation of high-
throughput VH:VL pairing and sequencing technology for antibody discovery without 
screening, and then compared the antibodies obtained from mining the VH:VL paired 
repertoire  with those obtained by yeast surface display. Here, I describe a novel antibody 
repertoire analysis and antibody discovery platform that is based on screening libraries of 
natively paired VH:VL sequences coupled with yeast display. This technology holds 
promise for interrogating the antibody specificity of the human repertoire isolated from 
peripheral B cells and is being used for the isolation of antibodies to influenza, Ebola 
(following vaccination) and to HIV-1 infection. This platform also enables epitope-
specific antibody discovery and affinity binning of the whole repertoire. The platform 
should be widely applicable for antibody repertoire analysis and antibody discovery for 
other pathogens. 
INTRODUCTION 
The high-throughput analysis and “mining” of the native antibody repertoires for 
isolation of antibodies that bind to desired antigens are yet to be demonstrated. Existing 
technologies for sequencing and expressing antibodies from B cells all have major 
limitations:  single B cell cloning suffers from very low throughput (usually at most a few 
hundred antibodies are expressed and characterized) (Georgiou et al., 2014b; Wilson and 
Andrews, 2012), while existing combinatorial library screening technologies rely on the 
screening of VH or VL libraries, and thus the native VH:VL pairing information found in B 
cells is not maintained (Bradbury et al., 2011). On the other hand, although high-
throughput VH:VL pairing and sequencing can generate sequence information about most 
native antibodies in the repertoire, only a very small number (< 100) of those antibodies 
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can be produced and assayed as a result of the cost for gene synthesis, and the extensive 
workload for cloning and expression (DeKosky et al., 2013; Georgiou et al., 2014b; 
Wang et al., 2015a, 2016). Furthermore, it is not a trivial task to select which antibodies 
to make (DeKosky et al., 2013; Wang et al., 2015a, 2016). So far, the three 
demonstrations that use high-throughput VH:VL paring for antibody discovery have relied 
on proteomic identification of the antibodies in the serum (DeKosky et al., 2013), or 
direct selection of highly expanded antibodies after immunization without screening 
(Wang et al., 2015a, 2016). Hence, a technology that enables high-throughput screening 
of native antibody repertoires without any special requirements is highly desirable. 
Furthermore, such a technology should enable linkage of antibody sequence-function 
relationships at the single clone level. 
RESULTS 
Implementation of novel yeast display platform for native antibody repertoire 
exploration 
In order to rapidly screen large antibody repertoires (libraries), one of the in vitro 
display methods has to be used, as recombinant expression of all antibodies in the 
repertoire in a soluble format with concomitant characterization is unrealistic. In contrast, 
after library transformation, every cell in the antibody display library expresses a single 
antibody from the repertoire, and this therefore allows detailed examination of every 
antibody. 
The first consideration for selection of a screening technology is the host for 
antibody library construction. Of all the display technologies, phage and E. coli display 
use E. coli as the host for antibody expression; yeast display uses yeast; while 
mammalian display uses mammalian cells (for example, HEK293). However, as antibody 
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library size is usually very small in mammalian cells (less than 105), I chose yeast 
display, as antibody library size can be as large as 1010 (similar to in E. coli).  
Furthermore, the similar protein production, folding, and secretion apparatus, and quality 
control mechanisms of yeast compared to those of mammalian cells make yeast a better 
host than E. coli. The use of FACS in yeast display also enables quantitative control of 
screening and normalization of affinity by surface expression level. Previous studies have 
also shown that yeast display, but not phage display, can recover native antibodies in the 
repertoire (Saggy et al., 2012; Wang et al., 2016), and compared to phage display, yeast 
display can identify more antibodies (Bowley et al., 2007). 
However, as high-throughput VH:VL pairing produces physically linked amplicons 
in which the 5’ end of VH is adjacent to the 5’ end to VL, the VH:VL paired repertoire can 
not be simply transferred into the display vector, in which the 3’ end of VH is adjacent to 
the 5’ end of VL (scFv). Hence, a new yeast display platform was designed. 
Design of the new platform 
In order to express the VH:VL pairs together, a galactose inducible bidirectional 
promoter was used to drive expression of both chains. CH1 (IgG1 isotype) and CL were 
fused at the C-terminus of VH and VL, respectively. To facilitate library construction, 4 
restriction enzyme sites that are very rarely found in immunoglobulin variable sequences 
were used (Fig. 4-1). As shown in Fig. 4-1, upon induction, the light chain was covalently 
linked to the heavy chain through a C-terminal disulfide bond, and the Fab fragment was 
displayed on the yeast cell surface as a N-terminal fusion of Aga2, which was linked to 
Aga1 by 2 disulfide bonds. C-terminal c-Myc and Flag tags were used to monitor 
expression of heavy and light chains, respectively. As antibodies have two different kinds 
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of light chains (κ and λ), whole repertoires were separated into two parts, and cloned into 
the κ and λ platforms (which used Cκ and Cλ2 domains), respectively. 
Compared to the scFv used in the original yeast display, the Fab fragment, which 
only requires fusion with the Fc domain, is much closer to a native IgG. Once desired 
clones are identified, they can be expressed as IgGs very easily without reformatting. 
In order to clone intact VH:VL pairs into the platform, NotI (which cuts at the C-
terminus of VL) and AscI (which cuts at the C-terminus of VH) were used first to digest 
the pairs, which were then ligated into similarly digested vectors. This ligation produces 
vectors with intact VH:VL pairs inserted. These vectors were then digested with NcoI 
(which cuts at the N-terminus of VL) and NheI (which cuts at the N-terminus of VH), and 
ligated with a similarly digested bidirectional promoter fragment. The vectors with intact 
VH:VL pairs were eventually transformed into yeast, and could be screened by FACS after 
induction. 
Verification of the new platform 
Initially, 13 anti-influzenza hemagglutinin antibodies (Lee, et al. in press) were 
tested in the new platform. Only 7 of them expressed well on the surface and showed 
binding to hemagglutinin. We hypothesized that inferior protein folding and secretion in 
yeast compared to human cells accounted for the poor expression of some antibodies. 
Moreover, the single disulfide bond between heavy and light chains may make Fab 
assembly inefficient in yeast compared to humans, and the lack of light chain expression 
for several antibodies on the yeast cell surface further suggested this. Thus, two methods 
were used to improve folding and assembly of the Fab. 
First, instead of EBY100, the strain that is commonly used for yeast display, we 
used the yeast strain AWY101 that overexpresses protein disulfide-isomerase (PDI) 
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(Wentz and Shusta, 2007). PDI is a protein folding chaperone that plays a critical role in 
antibody expression and folding (Feige et al., 2010). In AWY101, the overexpression of 
PDI is driven by the GPD promoter (a very strong constitutive promoter in yeast), and the 
whole cassette is integrated into the genome. We found that this innovation improved 
expression and binding of 3 antibodies that didn’t express well initially. 
Second, we fused a pair of leucine-zipper dimerization tags at the C-terminus of 
the heavy and light chains, respectively. At the C-terminus of the heavy chain, we put a 
basic leucine-zipper tag, and at the C-terminus of the light chain, we put an acidic 
leucine-zipper tag. The use of leucine-zipper tags should force better assembly of the 
heavy and light chains, and the strong interaction of basic and acidic leucine-zipper tags 
should promote heterodimerization of the heavy and light chains instead of 
homodimerization of heavy chains or light chains. The use of leucine-zipper tags 
improved expression and binding of the other 3 antibodies. 
We then combined the two methods. As shown in Fig. 4-2a, all of the tested 
antibodies, including 13 anti-influenza hemagglutinin antibodies (2 shown), 3 anti-Ebola 
GP antibodies (1 shown) (Corti et al., 2016; Lee et al., 2008), and 3 anti-HIV-1 bnAbs (1 
shown) (Doria-Rose et al., 2014; Kong et al., 2016; Wu et al., 2010), showed good 
surface expression and binding to their cognate proteins hemagglutinin, GP, and fusion 
peptide probes, respectively. The antibodies VRC01 and VRC26 were not tested for 
antigen binding due to the unavailability of the HIV-1 envelope trimer. 
In order to make sure that leucine-zipper mediated enhancement of Fab assembly 
didn’t interfere with binding, we made 3 chimeric antibodies that were composed of their 
native heavy chains and non-cognate light chains of other antibodies. As shown in Fig. 4-
2b, although the chimeric antibodies were still expressed on the surface, they didn’t bind 
to cognate antigens. The loss of binding for non-native antibodies, together with binding 
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to cognate but not to non-cogate antigens by native antibodies, indicated that leucine-
zipper mediated enhancement of the Fab assembly didn’t induce nonspecific binding. 
We also dissected the effects of combining chaperone overexpression and leucine-
zipper mediated assembly enhancement. As shown in Fig. 4-2c, both chaperone 
overexpression and leucine-zipper enhanced assembly improved expression and binding, 
and had additive effects in which the largest enhancement was seen when both of them 
were present. 
While this work was going on, Ojima-Kato et al.  also demonstrated the effect of 
leucine-zipper fusion on Fab expression and antigen binding in E. coli (Ojima-Kato et al., 
2016). This work serves as an independent verification of our incorporation of leucine-
zippers into Fab assembly. 
Exploration of native antibody repertoires 
Next, we analyzed 4 native antibody repertoires, including one of total B cells 
from PBMCs isolated 7 days after TIV01 vaccination (Lee et. al, in press), one of 
leukapheresis B cells collected 9 months after TIV01 vaccination, one of plasmablasts 
isolated 6 days after Ebola vaccine boost, and one of memory B cells collected 2 years 
after HIV-1 infection (Kong et al., 2016). The VH:VL paired libraries were separately 
amplified to construct VH:Vκ and VH:Vλ sub-libraries, which were then cloned into the κ 
and λ platforms, respectively. These libraries were then stained with fluorescently-labeled 
hemagglutinin, GP, and fusion peptide probes, and screened by FACS. Screening 
stringency was increased round-by-round by decreasing antigen concentrations: for 
influenza antibody repertoire screening, hemagglutinin was used at 1 μM, 200 nM, and 
then 40 nM concentrations; for the Ebola virus antibody repertoire, GP was used at 1 μM, 
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100 nM, and then 10 nM concentrations; and for the HIV-1 antibody repertoire, the 
fusion peptide probe was used at 1 μM, 100 nM, and then 10 nM concentrations.  
As shown in Fig. 4-3, in the HIV-1 VH:Vκ library, we saw a small population of 
cells that showed binding to the fusion peptide probe after 1 round of screening. After the 
2nd round of screening, significant enrichment of cells showing binding was observed. 
Similar enrichment of binding cells was also seen in the other repertoires after 3 rounds 
of screening.  
Toward functional screening: epitope-specific selection 
Another major limitation for most of the current antibody library 
screening/antibody discovery technologies is no function other than binding can be 
selected (Wilson and Andrews, 2012). The lack of functional selection methods in part 
results from a lack of simple and straightforward ways to link antibody function (for 
example, neutralization) to sequence. We therefore have also worked towards functional 
screening of antibody libraries.  
We have started by performing epitope-specific screening. We hypothesized that 
there is a higher chance to identify antibodies with desired functions (such as 
neutralization) from the pool of antibodies that target specific epitopes. This is supported 
by the fact that a large number of functional antibodies target specific, subdominant 
epitopes, especially for complex pathogens that have many immunodominant epitopes 
(such as Ebola and HIV-1 virus) (Corti and Lanzavecchia, 2013).   
We devised a strategy to fish out antibodies that target specific epitopes. We used 
the cloned anti-Ebola virus GP antibodies in a proof-of-principle study. In this set of 
antibodies, mAb 114, mAb 166, and c13c6 recognize similar epitopes (on the top of GP), 
while KZ52 and mAb 100 recognize similar epitopes (at the base of GP) (Corti et al., 
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2016; Lee et al., 2008). As expected (Fig. 4-4), mAb 114 binding to GP is blocked by 
itself, but not by KZ52, and c13c6 binding to GP is blocked by mAb166 and mAb 114, 
but not by KZ52, while KZ52 binding to GP is blocked by mAb 100 and itself, but not by 
mAb 114. This demonstrated that epitope-specific antibodies could be selected by first 
blocking undesired epitopes on the antigens. 
We screened the Ebola virus antibody repertoire using the epitope-specific 
approach. Fluorescently-labeled GP was blocked with KZ52, and then used for screening. 
We observed enrichment of cells binding to non-KZ52 epitopes after the 2nd round of 
screening. 
DISCUSSION 
Here, we developed a novel platform that enables high-throughput analysis of 
native antibody repertoires, and used it to explore antibody repertoires elicited after 
influenza and Ebola virus vaccination, and after HIV-1 infection. Compared to other 
antibody repertoire characterization and discovery methods, the new platform has several 
advantages: 1) it allows characterization of almost every antibody in the repertoire, and 
these antibodies have preserved their native VH:VL pairings; 2) use of FACS provides a 
high-throughput, quantitative way to characterize antibodies; and 3) NGS can still be 
used for sequence determination.  
Furthermore, we achieved epitope-specific antibody discovery with this platform 
by using antigens that were blocked with antibodies that targeted undesired epitopes. 
Starting from a pool of epitope-specific antibodies, we hypothesize there should be a 
higher chance to identify antibodies with desired functions (such as neutralization).  
Given these advantages, we anticipate the wide application of this new platform 
for antibody repertoire analysis and antibody discovery. 
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MATERIALS AND METHODS 
Cell line and media 
The yeast strain AWY101 (MATα AGA1::GAL1-AGA1::URA3 PDI1::GAPDH-
PDI1::LEU2 ura3-52 trp1 leu2Δ1 his3Δ200 pep4::HIS3 prb1Δ1.6R can1 GAL) was used 
for library construction and screening. Yeast cells were maintained in YPD medium (20 
g/l dextrose, 20 g/l peptone, and 10 g/l yeast extract); after library transformation, they 
were maintained in SDCAA medium (20 g/l dextrose, 6.7 g/l yeast nitrogen base, 5 g/l 
casamino acids, 8.56 g/l NaH2PO4.H2O, and 10.2 g/l Na2HPO4.7H2O). SGDCAA 
(SGCAA with 2 g/l dextrose) medium was used for library induction. 
Antigens and antibodies 
Hemagglutinins (A/California/07/2009, A/Solomon Islands/3/2006, 
A/Wisconsin/67/2005, and B/Malaysia/2508/2004) were provided by Dr. Stephen 
Harrison at Harvard University. Full-length and mucin-like domain deleted Ebola virus 
GP were provided by Dr. Nancy Sullivan at NIH. HIV-1 fusion peptide probe and knock-
out probe were provided by Dr. John Mascola at NIH. Anti-flag FITC antibody was 
purchased from Sigma-Aldrich (cat# F4049). Hemagglutinins were biotinylated using an 
EZ-Link Sulfo-NHS-LC-Biotin kit (Thermo Scientific). Chicken anti-c-Myc IgY, Alexa 
Fluor 633-goat anti-chicken IgG (GaC-633), streptavidin-PE (SA-PE) and streptavidin-
v450 (SA-450) were obtained from Invitrogen and BD Biosciences (cat# A-21281, A-
21103, S866, and 560797, respectively). Anti-biotin and streptavidin microbeads were 
purchased from Miltenyi Biotec (cat# 130-090-485 and 130-048-101). 
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Yeast library construction for influenza and Ebola vaccinees and HIV-1 elite 
controller 
VH:VL pairing was done as previously described (DeKosky et al., 2015). For 
library construction, 10 ng of VH:VL paired DNA was used as template for PCR to 
introduce NotI and AscI sites with primers that primes at 3’ of both chains. The product 
was digested, ligated with similarly digested vector, and transformed into E. coli. The 
libraries were minipreped, digested with NcoI and NheI, and ligated with similarly 
digested PCR product of bidirectional promoter. After transformation into E. coli, the 
libraries were minipreped and transformed into AWY101. The libraries were cultured in 
SDCAA medium at 30oC for 2 d. 
Library screening 
Cells were induced in SGDCAA medium at 20oC for 2 d. For the 1st round of 
selection, 109 cells (10-fold coverage relative to the number of transformants) were 
incubated with 1 µM biotinylated hemagglutinins at RT for 40 min and washed 
thoroughly with PBS+0.5% BSA+2 mM EDTA (PBSA) to remove any unbound 
hemagglutinins. Cells were then mixed with 400 µl of anti-biotin microbeads and 
incubated at 4oC for 15 min, and washed again. Cells that bound hemagglutinins were 
selected using MidiMACS system (Miltenyi Biotec), and recovered in SDCAA medium 
at 30oC. For the 2nd round of selection, 108 cells in 1ml PBSA were labeled with 1 µM 
biotinylated hemagglutinins and 4 µg/ml chicken anti-c-Myc IgY and anti-flag FITC at 
RT for 40 min. After washing with PBSA, cells were incubated with 5 µg/ml SA-450 and 
5 µg/ml GaC-633 at 4oC for 15 min. After washing, cells were resuspended in PBSA 
buffer and sorted using FACS Aria (BD Bioscience). The subsequent rounds of selection 
were performed in a similar way, except that the concentration of hemagglutinins used 
was decreased to 200 nM and 40 nM, respectively. 
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Figure 4-1: Design of the new platform.  
(a) Structure of the new vector. (b) Fab fragments displayed on yeast cell surface. (c) 
Cloning strategy for paired library construction. In the first step, NotI and AscI digested 
VH:VL pairs is ligated with similarly digested vectors. In the second step, NcoI and NheI 











Figure 4-2: Verification of the new platform.  
(a) Binding of hemagglutinin (left two panels), Ebola GP (the third panel), and HIV-1 
fusion peptide (rightmost panel) antibodies to their cognate antigens. In left two panels, 
binding to cognate hemagglutinin (A/California/07/2009 and B/Malaysia/2508/2004, 
respectively) is shown in red, and to noncogate hemagglutinin (B/Malaysia/2508/2004 
and A/California/07/2009, respectively) is shown in blue. In right two panels, binding is 
monitored in APC channel, and light chain expression is monitored in FITC channel. (b) 
Binding of native and chimeric hemagglutinin antibodies to cognate antigens. Native 
antibody is shown in red, and chimeric antibodies are shown in blue and orange. (c) 
Effects of chaperone overexpression and leucine-zipper fusion on binding of a 
hemagglutinin antibody to cognate antigen. Red, blue, orange, and green denotes binding 
with both, with leucin-zipper fusion only, with chaperone overexpression only, and 




Figure 4-3: HIV-1 elite controller library screening.  
(a) VH:Vκ library after 1st round of screening with fusion peptide probe. (b) VH:Vκ library 















Figure 4-4: Epitope specific staining of antibodies.  
(a) Ebola GP antibody 114 was stained with 114 blocked GP (red), and KZ52 blocked GP 
(blue). (b) c13c6 was stained with 114 blocked GP (red), 166 blocked GP (blue), and 
KZ52 blocked GP (orange). (c) KZ52 was stained with KZ52 blocked GP (red), 100 















Chapter 5: Conclusion 
The immune system plays a very important role in human health, as it can not 
only protect from astronomical number of pathogens, but also keep from self-destruction 
(autoimmunity). Adaptive immunity is one of the two branches of the immune system, 
which is the basis of the diversity of recognition and protection. Antibodies are an 
important class of mediators in adaptive immunity, which not only neutralize pathogens, 
but also destroy them by recruiting innate immune effectors (for example, NK cells, 
macrophages, and complement). As a result of their high specificity, affinity, and 
stability, antibodies are widely used in basic research and clinics. Moreover, 
characterization of the antibody repertoires elicited after vaccination or infection is also 
of great importance, which can provide insights about how to design more effective 
vaccines. Thus, antibody discovery and repertoire analysis technologies are critical. 
The work described here presents high-throughput technologies for antibody 
discovery and repertoire analysis, and protein engineering for rationally manipulating 
adaptive immunity. Compared to existing technologies, these novel approaches have 
multiple advantages and shed light on further efforts for improvement, which will be 
detailed below. The applications and implications of these approaches will also be 
discussed. 
ADVANTAGES OF NATIVE ANTIBODY LIBRARY SCREENING COUPLED WITH NGS OVER 
OTHER EXISTING ANTIBODY REPERTOIRE MINING AND DISCOVERY TECHNOLOGIES 
An important consideration in antibody repertoire analysis is throughput, as 
analyzing all sequences in a large repertoire one by one is laborious and expensive. 
Another important consideration is intactness of native repertoire (native VH:VL pairing), 
which is lost in most cases. Single-cell RT-PCR can keep the native repertoire intact, but 
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its throughput is relatively low, which only permits interrogation of a fraction of the 
complete repertoire. On the other hand, NGS has very high throughput, but it disrupts the 
native repertoire during library preparation. Compared to the two technologies, native 
antibody library screening by yeast display coupled with NGS is like an ultra fast single-
cell RT-PCR, which combines the advantages of both methods. First, native pairing of 
VH:VL is achieved in high-throughput emulsion based pairing, and conserved during 
antibody library construction and screening, which outcompetes normal NGS. Second, 
the use of yeast display provides a means to rapidly screen the library quantitatively (with 
FACS). Evolutionarily, yeast is closer to human than E. coli, which serves as a better host 
for antibody expression as a result of its protein folding and secretory, and quality control 
pathways. Previous studies have also shown that yeast display can recover native 
antibodies from the repertoire (Wang et al., 2016), and allow identification of more 
diverse antibodies than phage display (Bowley et al., 2007). Moreover, yeast is more 
manipulative than human cell lines (for example, HEK293), which allows construction of 
large enough library for repertoire analysis (sizes of the libraries described here are 
usually between 108 and 109, which is more than enough for characterization of common 
antibody repertoires, and 1010 is achievable with some efforts). The use of FACS for 
library screening is also advantageous, as FACS is robust and fast, which allows 
screening of 108 library members in several hours. Moreover, multiple compatible colors 
used in FACS nowadays allows fine tune of screening, which is critical for some 
applications. In regards to throughput of screening, the platform also outcompetes both 
methods. Third, both NGS and Sanger sequencing can be used in the platform. When 
antibody repertoire analysis is needed, NGS can be used to probe all the antibodies in the 
library after each round of screening, while when hits are needed (for antibody 
discovery), Sanger sequencing can be used to sequence the highly enriched clones. 
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Compared to existing antibody discovery technologies, the platform is also 
advantageous. The increase in throughput makes the platform superior than B cell 
immortalization, and the use of yeast as antibody expression host makes it better than 
phage display, while Fab used in screening avoids the trouble of reformatting scFv into 
IgG. An even larger improvement is the preservation of native VH:VL pairing in the 
library. Non-cognate VH:VL pairing has been shown to result in unfavorable properties in 
engineered antibodies (for example, instability) (Jayaram et al., 2012; Ponsel et al., 2011; 
Tiller et al., 2013), which requires additional efforts to fix. Thus, the platform should 
allow identification of promising antibodies with superior biophysical properties. 
One limitation of the platform is it doesn’t enable functional selection besides 
binding. Functional selection is highly desirable, as many antibodies do not neutralize or 
protect besides just binding. However, functional selection is very difficult to achieve, as 
there is no simple method to link antibody sequences with their functions. The only 
demonstration of functional selection is B cell immortalization, in which antibodies 
secreted by single B cells can be functionally screened (for example, neutralization). On 
the other hand, functional selection by the platform can be achieved by smart design of 
the selection. For example, when isolating antibodies against HIV-1 or influenza virus, 
specific antigens that only display broadly neutralizing epitopes or intact antigens that are 
blocked with antibodies targeting undesired epitopes can be used, which allows 
identification of broadly neutralizing epitope specific antibodies. There is a higher chance 
that bnAbs can be isolated from these broadly neutralizing epitope specific antibodies. 
FUTURE APPLICATION AND DIVERSIFICATION OF THE PLATFORM 
In the work described here, the platform is used to analyze antibody repertoires 
elicited after Ebola and flu vaccination and HIV-1 infection. I foresee application of the 
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platform for analysis of more antibody repertoires and discovery of promising therapeutic 
antibodies. Specifically, a naïve human VH:VL natively paired antibody library can be 
constructed, which can be used to isolate antibodies against various pathogens. 
Moreover, as a result of the similarity between TCR and antibody, the platform 
can be applied for TCR repertoire analysis and discovery. T cell is indispensible in 
adaptive immunity as it provides help for B cell and executes cytotoxicity. Thus, a high-
throughput technology for analyzing native TCR repertoire is invaluable. Moreover, as 
there are more and more needs for cancer neoantigen specific TCRs to be used in TCR 
transgenic T cells for cancer immunotherapy, the platform can be used to isolate these 
TCRs. Similar to naïve antibody library, a naïve human Vα:Vβ natively paired TCR 
library can be constructed for antigen specific TCR mining, and as T cells don’t undergo 
somatic hypermutation, these isolated TCRs can be directly used without further affinity 
maturation. 
A potential diversification of the platform is making it dual mode: selection and 
secretion. By incorporating an amber codon (TAG) at the end of heavy chain and 
introducing a suppressor tRNA with its cognate aminoacyl-tRNA synthetase, the 
platform can be switched between two modes. In selection mode, a noncanonical amino 
acid is supplied, which will be incorporated at the TAG codon by tRNA and its 
synthetase. This will anchor the Fab on the surface of yeast for selection. In secretion 
mode, without the noncanonical amino acid, translation will stop there, which makes 
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